BrainAurora Medical Technology Limited

脑动极光医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

Stock Code: 6681



2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

CONTENT

2 ABOUT THIS REPORT
2 Scope of Report
2 Data Description
2 Report Language
2 Basis of Preparation
3 ABOUT BRAINAURORA
3 1. Company Profile
5 2. Honorary Awards
8 SUSTAINABILITY MANAGEMENT
8 1. Statement by the Board
9 2. ESG Strategy and Governance Structure
10 3. Communication with Stakeholders
12 4. Analysis of Materiality Issues
13 I. STABLE AND LONG-TERM DEVELOPMENT BASED ON COMPLIANCE
13 1. Internal Control Compliance
15 2. Business Ethics and Anti-Corruption
16 II. HEART AND BRAIN PROTECTION WITH QUALITY FIRST
16 1. Product Quality and Safety
16 (1) Quality Management System Construction
18 (2) Quality Management Measures
19 (3) Quality Management of Clinical Trials
21 2. Improving Customer Service Quality
21 (1) Service Standardization Construction
22 (2) Focusing on Patient and User Experience
24 (3) Strengthening Data Security Defense Lines
30 (4) Responsible Marketing
31 3. R&D and Innovation
31 (1) Digital Science and Technology Innovation
35 (2) Industry Empowerment
40 (3) Intellectual Property Protection
40 III. GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES
40 1. Strengthening Emission Control
41 (1) Non-hazardous Wastes
41 (2) Hazardous Wastes
41 (3) Waste Water
42 2. Optimizing the Resource Utilization
42 (1) Saving Electricity
43 (2) Saving Water
43 (3) Green Office
44 3. Addressing Climate Change
44 (1) Governance
45 (2) Strategy
49 (3) Risk Management
49 (4) Metrics and Targets
51 IV. TALENT ORIENTATION AND CONCERTED PROGRESS
51 1. Compliant Employment
53 2. Compensation and Benefits
54 3. Health and Safety
54 4. Development and Training
57 V. WIN-WIN COOPERATION AND JOINT PROGRESS
57 1. Sustainable Supply Chain
57 (1) Supplier Quality Management
58 (2) Supply Chain ESG Management
59 (3) Supplier Integrity Management
59 (4) Supplier Communication
60 2. Public Welfare and Charity
61 Appendix
61 Appendix 1 Key Performance Table
65 Appendix 2 Index Table of the Environmental, Social and Governance Reporting Code of the Hong Kong Stock Exchange

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

ABOUT THIS REPORT

This is an environmental, social and governance (ESG) report (hereinafter referred to as the "ESG Report" or "this Report") prepared and issued by BrainAurora Medical Technology Limited (hereinafter referred to as "BrainAurora", the "Company" or "we"), which aims to objectively and impartially disclose the Company's management, practices and performance in ESG, and respond to the expectations and concerns of all stakeholders.

Scope of Report

This Report covers the performance of BrainAurora Medical Technology Limited in environment, society and governance. The reporting period is from January 1, 2025 to December 31, 2025, and some content exceeds the above scope.

Data Description

The information and data of this Report are mainly derived from our internal company documents and reports, relevant statistical reports, stakeholder surveys and relevant public information. The Company's emissions and energy use indicators are counted and calculated in accordance with national regulations or international standards. Unless otherwise specified, the monetary amounts involved in this Report are measured in RMB.

Report Language

This Report is published in Chinese and English. If there is any difference, please refer to the Chinese version.

Basis of Preparation

This Report is prepared in accordance with the Environmental, Social and Governance Reporting Code (hereinafter referred to as the "ESG Reporting Code") in Appendix C2 of the Main Board Listing Rules issued by The Stock Exchange of Hong Kong Limited (hereinafter referred to as the "Hong Kong Stock Exchange"), with materiality, quantification, balance and consistency as the reporting principles, and following the "Comply or Explain" clause set out in the ESG Reporting Code to report on ESG topics and data.

"Materiality" principle: The main stakeholders and their ESG topics of concern have been identified in this Report during its preparation process, and targeted disclosures were made in this Report based on the relative importance of their topics of concern.

"Quantification" principle: This Report shows key performance indicators at the environmental and social levels by quantitative data. The measurement standards, methods, assumptions and/or calculation tools of the key performance indicators in this Report, as well as the sources of conversion coefficients used, have been explained in the corresponding parts.

"Balance" principle: This Report objectively and impartially presents the Company's ESG performance, avoiding selections, omissions or reporting formats that may inappropriately affect the decision-making or judgment of the report readers.

"Consistency" principle: This is the second Environmental, Social and Governance (ESG) Report issued by BrainAurora Medical Technology Limited. Unless otherwise specified, the key performance indicators and data statistical methods consistent with those in this Report will be used in the future to provide readers with meaningful comparisons of the Company's ESG information.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

ABOUT BRAINAURORA

1. Company Profile

BrainAurora is a seasoned player in China's cognitive impairment digital therapeutics market. It is also the first Chinese enterprise to successfully develop a medical-grade DTx product for cognitive impairment by integrating brain science with cutting-edge artificial intelligence technologies. Our product pipeline covers the assessment and intervention of a wide range of cognitive impairments induced by vascular diseases, neurodegenerative diseases, psychiatric disorders, childhood developmental defects, and other conditions. Among them, our core product is the first cognitive impairment DTx product that has obtained regulatory approval in China.

Our mission: Accelerate the diagnosis and treatment of brain health diseases

Our vision: To become the world's leading company in cognitive impairment DTx technology

Our values: Patient-oriented, scientific evidence-based, innovative and creative, win-win cooperation

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Company History

Year	Event
2012	• BrainAurora Zhejiang was founded in the PRC.
2014	• We cooperated with Chinese Association for Mental Health (中國心理衛生協會) in relation to qualification training sessions for cognitive training.
2017	• We cooperated with Xuanwu Hospital in relation to conducting research on cognitive training clinics.
2018	• We obtained the initial Class II medical device registration certificate for the Brain Function Information Management Platform Software System, our core product, from the Hunan MPA.
2020	• We extended the scope of the medical device registration certificate for our core product to include eight indications, including vascular cognitive impairment, Alzheimer's disease, aphasia, depression, schizophrenia, sleep disorder, ADHD and autism; • We cooperated with Chaoyang Hospital to help establish the first cognitive center adopting DTx in China.
2021	• We cooperated with National Health Commission Capacity Building and Continuing Education Center (國家衛生健康委能力建設和繼續教育中心) in relation to cognitive disorder diagnosis and treatment specialist capacity building.
2022	• We obtained a Class II medical device registration certificate for the Cognitive Ability Supplemental Screening and Assessment Software from the Hunan MPA; • We obtained CE mark for our Cognitive Impairment Treatment Software in the EU; • We obtained a Class II medical device registration certificate for the Basic Cognitive Capability Assessment Testing Software from the Hunan MPA.
2023	• We obtained a Class II medical device registration certificate for Dyslexia Supplemental Screening and Assessment Software from the Hunan MPA.
2024	• We were awarded the Global Innovative Award for Digital Therapeutics in Cognitive Disorders at the Sullivan Growth, Innovation & Leadership (GIL) Annual Gala.
2025	• We were selected as a "Typical Artificial Intelligence Case" at the Global Digital Economy Conference.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

2. Honorary Awards

- BrainAurora cognitive DTx AI diagnosis and treatment platform won the award of "Data × AI Scenario Benchmark Case" issued by DTinsight China Digital Intelligence Development Research Center



- BrainAuGPT large model of Beijing Zhijingling, a subsidiary of BrainAurora, won the award of "Data × AI Scenario Benchmark Case" issued by DTinsight China Digital Intelligence Development Research Center




ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

- The case of "Application of Personalized Intervention Technology based on Cognitive Deep Reasoning Large Model in the Medical Field" developed by BrainAurora was successfully shortlisted for the "Beijing Artificial Intelligence Empowering Industry Development Typical Cases (2025)" of the Global Digital Economy Conference 2025



- The "Cognitive DTx Security Management Platform" developed by BrainAurora won the "Pan'an" Excellent Case in the Medical Field awarded by the Global Digital Economy Conference 2025



ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

- BrainAurora's "Personalized Intervention Technology Based on Cognitive Deep Reasoning Large Model" won the "2025 Digital Intelligence Innovation Benchmark Case" at the Beijing-Tianjin-Hebei CIO Digital Intelligence Innovation Conference 2025 hosted by DTinsight China Digital Intelligence Development Research Center



- Cai Longjun, CEO & CTO of BrainAurora, won the individual award of "2025 Digital Intelligence Innovation Pioneer" for his innovative practice of large model technology in the field of diagnosis and treatment of cognitive impairment diseases



ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

SUSTAINABILITY MANAGEMENT

1. Statement by the Board

Our Board attaches great importance to ESG governance and regards it as an important cornerstone for the Company's long-term sustainability. As the highest decision-making authority on ESG matters, the Board is fully responsible for comprehensively coordinating the Company's ESG strategic planning, goals and management policies, supervising the effective implementation of ESG-related policies, and regularly evaluating the progress and effectiveness of ESG work, existing deficiencies and improvement directions, to ensure that ESG factors are deeply integrated into all aspects of the Company's strategic decision-making, business operations, risk management and culture construction, promoting the coordinated development of corporate value and social value.

ESG Regulatory Matters

The Board incorporates ESG management into the Company's core governance system, clarifies the responsibilities of the management in ESG matters, and establishes a systematic reporting mechanism. In 2026, the Board has reviewed and approved the ESG report for this year to ensure that ESG management and the Company's business development goals are promoted in a coordinated manner.

ESG Strategy and Risk Management

By integrating the requirements of ESG governance into its day-to-day management system, we systematically identify ESG (including climate change) risks and opportunities, formulate response strategies, and prioritize and manage ESG-related issues based on industry trends, regulatory requirements and stakeholders' expectations. The Board regularly listens to the management's reports on major ESG topics, including environmental goal setting, social responsibility fulfillment and corporate governance optimization, to ensure that the ESG strategy is consistent with the Company's overall development direction, enhancing the Company's ESG risk prevention and control capabilities and sustainable development resilience.

ESG Goals and Continuing Improvement

BrainAurora continues to promote key ESG goals such as carbon emission management, waste management, energy management and water resource management around climate change and resource management issues highly related to business operations. The Company has comprehensively reviewed and evaluated the progress of the implementation of ESG goals for this year, and updated and optimized relevant ESG goals based on the review results and actual business development. The Board will continue to monitor the implementation of ESG goals, regularly evaluate goal completion progress, and promptly optimize and adjust implementation strategies to promote the continuous upgrading of ESG work. At the same time, the Board commits to transparently disclosing relevant progress to stakeholders through the annual sustainability report, effectively fulfilling corporate social responsibilities.

The Board of the Company has reviewed and approved this Report on March 31, 2026.

Board of Directors
BrainAurora Medical Technology Limited
March 31, 2026

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

2. ESG Strategy and Governance Structure

We firmly believe that the Company's sustainable development is closely related to environmental, social and governance responsibilities, and a complete ESG governance system is an important cornerstone to support the Company's high-quality development. By continuously improving the ESG governance structure and relevant processes, we deeply integrate the concept of sustainable development into the entire process of corporate operations and management, effectively prevent ESG risks while steadily achieving operating goals, and actively fulfill environmental and social responsibilities.

ESG Governance Structure

We have built a systematic ESG governance structure, clarifying responsibilities at all levels to ensure the orderly advancement of ESG work. As the highest responsible body for the Company's ESG governance, the Board comprehensively coordinates and leads the Company's ESG-related work, assesses potential risks in the ESG field, and establishes ESG management and internal monitoring mechanisms to provide top-level guidance for ESG work.

The Board has an ESG committee, which is mainly responsible for formulating overall ESG goals and development strategies, reviewing ESG-related policies, and ensuring that various initiatives comply with national laws and regulations and relevant industry standards. At the same time, the Company has established an ESG working group comprising heads of our business departments, which shall be responsible for the specific execution of the ESG strategies, and act as an important bridge connecting strategic planning and on-the-ground execution to ensure that ESG initiatives are effectively implemented. The ESG working group regularly reports work progress to the Board and the ESG committee, and accepts the supervision of the Board, forming a closed-loop management, and providing a guarantee for the realization of the Company's sustainable development goals.

ESG Strategy and Management Mechanism

The Company continues to improve the ESG management mechanism and deeply integrates sustainable development goals into the business development strategy to ensure that the ESG concept runs through all aspects of corporate operations. At the same time, the Company pays attention to cultivating the ESG concept of all employees, regularly conducts sustainable development-related training, and gradually improves the environmental awareness and professional capabilities of employees; actively responds to the call of society, participates in various social public welfare undertakings, and effectively fulfills corporate social responsibility. While pursuing operating benefits, the Company is always committed to creating long-term value for all stakeholders, promoting the harmonious coexistence of enterprises with the environment and society, and assisting the Company to achieve high-quality and sustainable development.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

3. Communication with Stakeholders

Our external stakeholders mainly include shareholders and investors, government and regulatory authorities, collaborating hospitals, patients, suppliers, media, community members and public welfare organizations; internal stakeholders mainly include board members, senior managers and employees. We have established effective communication channels to actively collect and respond to the concerns of all stakeholders on the Group's ESG topics, and the suggestions obtained are used as an important reference to guide the Company's ESG work.

Stakeholder groups	Key communication channels	Key matters of concern
Shareholders and investors	• Investor meetings • General meetings • Corporate announcements and circulars • Investor relations column • Questionnaires	• Corporate governance • Financial performance • Stable returns • Risk management
Government and regulatory authorities	• Major meetings • Policy consultation • Event reports • Institutional inspections • Information disclosure	• On-time payment of taxes • Law and regulation compliance • Energy saving and emission reduction • Industry impact
Collaborating hospitals	• Cooperation meetings • Field visits • Satisfaction surveys • Complaint channels • Questionnaires	• Customer service • Privacy protection • Industry impact • Business ethics • Mutual benefit and win-win situation
Patients	• Patient satisfaction surveys • Daily communication • Service complaints and feedback channels	• Product and medical service quality • Patient privacy protection • Community investment
Suppliers	• Bidding and procurement activities • Field visits • Regular reviews • Questionnaires	• Business ethics • Mutual benefit and win-win situation • Payment process
Board members	• Board meetings • Committee meetings • Annual reports of the Company • Questionnaires	• Strategic planning • Risk management • Financial performance • Ethical standards

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT


Stakeholder groups	Key communication channels	Key matters of concern
Senior managers	• Meetings and talks • Employee activities • Phone/email • Work reports • Questionnaires	• Strategic execution • Financial performance • Operational efficiency • Public relations
Employees	• Work meetings • Staff meetings • Performance appraisals • Employee complaint channels • Questionnaires	• Compensation system • Employee rights • Health and safety • Communication mechanism
Community members and public welfare organizations	• Public welfare activities • Open days • Questionnaires • Corporate announcements and circulars	• Community investment • Communication mechanism • Compliance with laws and regulations • Industry impact
News media	• Performance conferences • News specials • Questionnaires	• Technological innovation • Industry impact • Ecological and environmental protection

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

4. Analysis of Materiality Issues

In order to identify key areas of corporate environmental, social and governance practices and meet the needs of stakeholders, BrainAurora conducted questionnaires to understand the suggestions and expectations of stakeholders on the Group's response to environmental, social and governance topics. Based on the results of the questionnaires, we identified 12 ESG-related topics and drew up an analysis matrix of ESG material topics for 2025.

BrainAurora 2025 ESG Issues Materiality Matrix



ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

I. STABLE AND LONG-TERM DEVELOPMENT BASED ON COMPLIANCE

1. Internal Control Compliance

BrainAurora always adheres to compliant operations and integrity in practice as the core cornerstone of sustainable corporate development, and strictly complies with domestic and foreign laws, regulations, and regulatory rules. The Company strictly abides by relevant laws and regulations, including but not limited to the Company Law of PRC (《中華人民共和國公司法》), the Cayman Companies Act (《開曼公司法》), the Securities Law of the People's Republic of China (《中華人民共和國證券法》) and the Listing Rules (《上市規則》) of the Hong Kong Stock Exchange, and deeply integrates the compliance concept into our governance structure and the entire business process. Relying on internal systems such as the Risk Compliance System, the Code of Compliance Conducts, and the Evaluation Manual for Risk Assessment and Internal Control Compliance, we implement the internal control concept of "management systematization, system processization, and process informatization", and build a strict, standardized, comprehensive and effective internal control system oriented to risk management and focusing on compliance management, forming a risk prevention and control mechanism that covers all aspects, involves all employees, runs through the entire process and involves the entire system. Besides, we are committed to achieving the management and control goals of "strengthening internal control, promoting compliance, and preventing risks", providing a solid guarantee for the Company's high-quality development.

We continue to improve the risk management system, formulate risk management system, and adopt a risk management model that combines classification management with the "three lines of defense". Besides, we implement differentiated management and control measures for the compliance risks of different business aspects in combination with industry development trends and the Company's actual business, identify and manage related risks, and specify in detail the procedures for preventing, controlling and mitigating risk events before, during and after the events. We have also built an internal control "three lines of defense" consisting of the management department, lead management department and audit supervision department. Each department has a clear division of work and cooperates with each other to form a joint force for risk prevention and control. The Company's risk assessment and monitoring process are as follows:

Risk identification and information collection • Each department collects risk information, covering strategic risk, market risk, financial risk, operational risk, legal and compliance risk, etc., and summarizes, analyzes and dynamically manages the collected risk information;
Risk assessment and classification • The Company implements classification management on risks, establishes a systematic risk list, and dynamically adjusts it according to changes in internal and external situations and the results of risk identification and analysis; • The Company conducts risk assessment at least once a year, which assesses risks from multiple dimensions based on standards and appetites, determines four levels of major risk, important risk, medium risk and low risk, and forms an annual risk assessment report.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Formulation of risk management strategy • Focusing on the Company's development strategy and business objectives, and based on its own conditions, business characteristics and external environment, determine the risk management strategy, clarify risk appetites and tolerance; • According to the risk management strategy, formulate risk management solutions for various risks, including specific risk resolution goals, involved processes, required resources, and response measures taken before, during and after risk events.
Risk monitoring and early warning • Establish and improve the risk monitoring indicator system, carry out risk quantification work in key areas, improve the early warning mechanism, realize real-time monitoring and early warning; • Relevant departments are responsible for the design, monitoring and reporting of indicators in their fields, and the lead department is responsible for overall monitoring, summary analysis, notification and reminder, and supervising the implementation of the plan.

We have developed comprehensive audit management policies and procedures to ensure that the Company's operating records are reliable and accurate. We regularly conduct on-site internal audits to monitor the implementation of internal control policies, report to the management and the audit committee, and follow up on the recommended corrective measures. In addition, we continue to improve the existing compliance management system, and actively carry out compliance awareness training for employees to popularize and enhance compliance management awareness, so that every employee can internalize compliance requirements into their own codes of conduct.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

2. Business Ethics and Anti-Corruption

BrainAurora adheres to the business principle of integrity and strictly abides by the Law of the People's Republic of China on Anti-money Laundering (《中華人民共和國反洗錢法》), the Anti-Unfair Competition Law of the PRC (《中華人民共和國反不正當競爭法》)and other laws and regulations. We have also formulated strict and comprehensive internal policies, issued management policies such as the Anti-Corruption and Anti-Commercial Bribery System, the Anti-Fraud Policy and the Anti-Money Laundering Policy, and clarified the supervision mechanism and responsibilities for anti-fraud work. We require all employees to abide by the code of professional conducts, prohibit bribery, corruption and other non-compliant activities in the course of operations and management, and have a zero-tolerance attitude towards any form of illegal and non-compliant behaviors.

We implement a commitment system for preventing commercial bribery in important positions and processes, and require all staff in important positions and processes to sign the Anti-Corruption and Anti-Commercial Bribery Commitment. In addition, the Company regularly conducts compliance training and annual ethics training to strengthen integrity publicity and education, and continue to deepen the construction of compliance culture. During the year, we organized 1 anti-corruption training session for all members of the Board and employees.

We have also opened an internal reporting and escalation mechanism, and established a mailbox for filing related complaints or whistleblowing reports, so as to encourage employees to report any actual or suspected fraud cases, information that violates professional ethics, and other suspicious activities. At the same time, we have put in place whistleblower protection mechanism to strictly keep the name, department, company and other information of the whistleblower confidential throughout the entire process of reporting acceptance and investigation, and it is strictly forbidden to disclose it to the involved party or related units. Any form of retaliation is strictly prohibited. The Company will severely punish any violation of confidentiality regulations, disclosure of whistleblower information, or retaliation against the whistleblower. For serious cases that constitute a crime, we will transfer them to judicial authorities for criminal prosecution in accordance with the law to effectively protect the legitimate rights and interests of the whistleblower.

Email for whistleblowing reports: brainau.rrg@66nao.com

During this year, BrainAurora has not received any concluded corruption cases, nor has there been any litigation cases involving embezzlement, bribery, or fraud.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

II. HEART AND BRAIN PROTECTION WITH QUALITY FIRST

1. Product Quality and Safety

(1) Quality Management System Construction

BrainAurora has always regarded the quality management system as the core support for the sustainable development of the enterprise, adhered to the bottom line of compliant operation and protection of users' rights and interests, and is committed to building a scientific and perfect quality control system. The Company strictly abides by the Product Quality Law of the PRC (《中華人民共和國產品質量法》), the Supervision and Administration of Medical Devices (《醫療器械監督管理條例》), the Good Manufacturing Practice for Medical Devices (《醫療器械生產質量管理規範》), the Guiding Principles for the Classification of AI-based Medical Software Products (《人工智能醫用軟件品分類界定指導原則》), the Guiding Principles for the Classification of Rehabilitation Digital Therapeutics Software Products (《康復類數字療法軟件產品分類界定指導原則》) and other laws, regulations and industry standards, and according to the NMPA regulations, the ISO 13485 international standard and the Good Manufacturing Practices (《藥品生產質量管理規範》) (GMP) requirements, formulates strict internal specifications for product design and development to ensure compliance and controllability of the entire process of quality management. Prior to product registration, the Company strictly follows its own product technical requirements and related standards such as GB/T25000.51 and GB/T9706, and selects inspection institutions with CMA qualifications to conduct product testing and issue compliance inspection reports. In terms of internal quality management, the Company strictly follows the requirements of China GMP to formulate a clear hierarchy of internal inspection control systems, covering general programmatic documents, various procedural documents, system documents and supporting documents, forming a management system with clear rights and responsibilities, standardized processes and traceable data, and at the same time implements process inspection and finished product inspection combined with the characteristics of different products to ensure that all products fully comply with legal and regulatory requirements before ex-factory release, laying a solid institutional foundation for the quality and safety of all types of products.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

The Company has established a comprehensive quality management system, integrating quality control throughout the entire product lifecycle, strictly regulating all aspects from research and development to the transformation of results, and implementing standardized management on key elements such as personnel qualifications, facilities and equipment, and documentation. During the product design and development stage, the Company established three core control systems, and professional third-party organizations carried out independent supervision and evaluation on the implementation of the systems to further ensure research and development compliance and product quality reliability. To achieve full-process quality traceability, the Company has also deployed a traceability control system, a software traceability analysis platform and a UDI (unique device identification) system to ensure the traceability of products throughout the product lifecycle.

Design and development control system	Configuration management control system	Risk management control system
Strictly regulate the entire process of R&D activities from demand analysis, protocol design to product delivery, and ensure that each development stage complies with established standards and specifications, to ensure the compliance and stability of product design from the source;	Maintain the consistency and integrity of each component of the product through version control and change management, realize the traceability of configuration information, and ensure quality stability during the product iteration process;	Systematically identify, evaluate and control potential risks throughout the product lifecycle, formulate and implement targeted risk mitigation measures, to minimize quality and safety hazards and ensure the reliable operation of the product throughout its lifecycle.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

(2) Quality Management Measures

With the core objectives of ensuring the quality of product development, BrainAurora has established a full-process quality management mechanism that prioritizes scientific validity, patient compliance and R&D efficiency, providing a solid guarantee for the reliable implementation of cognitive digital therapeutics products. Before starting a product development project, the Company accurately identifies patients' needs and product positioning through systematic market research, and forms a development proposal covering target medical needs, potential risks and core functions. After review and approval by the management, it is refined into an executable detailed development plan, anchoring the quality direction from the source.

The Company breaks down the entire product R&D process into three core phases and implements refined quality control. Through professional division of labor and closed-loop management at each phase, the development quality is controlled at every level from scientific demonstration, product design to functional verification. Each phase is led by an exclusive team, which ensures the scientific and rigorous technical path while balancing user experience and clinical value, providing a full-chain guarantee for the final effect of the product.

- **Basic research phase**
  Led by the Brain Research Institute, a core talent agency within the R&D team, in-depth special research is carried out based on existing scientific theories and clinical data. Through systematic scientific demonstration and cross-departmental discussion, the core design parameters of the product are accurately established. This phase focuses on the scientificity and effectiveness of the technical path, lays a rigorous technical foundation for the subsequent R&D of the product, and ensures the clinical adaptability and technical compliance of the product from the source.

- **Product planning phase**
  The Product Innovation Center is responsible for carrying out top-level product design by deeply integrating the research results of the Brain Research Institute strictly based on the scientific framework established in the early stage. During the design process, fun elements such as gamification are actively incorporated. Under the premise of ensuring that product functions match clinical needs, the user experience and market attractiveness of the product are effectively enhanced, balancing the clinical value of the product and patient compliance.

- **Development and testing phase**
  Specifically executed by the Technology Research Center, the team strictly builds an internal beta version of the product based on standardized testing plans, and collects complete feedback data through multi-dimensional user testing and systematic questionnaires. Comprehensively evaluate the completeness of product functions, the fun of user experience and the effectiveness of brain function stimulation, and carry out multiple rounds of optimization and adjustment based on the evaluation results until all indicators of the product reach preset standards to complete quality verification.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

To ensure the effective implementation of the quality management system, the Company has established a normalized training mechanism, requiring all R&D personnel to participate in special quality management training regularly, and including other key departments such as quality control, human resources and marketing in the training scope to strengthen the quality awareness of all employees. At the same time, the Company has established a complete emergency handling mechanism for quality incidents, clarifying emergency procedures and response requirements such as product recalls. As of the end of 2025, no adverse quality events requiring the initiation of recall procedures have occurred, practically safeguarding patient rights and corporate reputation.

(3) Quality Management of Clinical Trials

Compliance System and Management Mechanism

In the entire process of medical device R&D, strict clinical trial quality management is the core cornerstone for guaranteeing product safety and effectiveness. The Company strictly complies with domestic regulations such as the Good Clinical Trial Practice for Medical Devices (《醫療器械臨床試驗質量管理規範》), and actively benchmarks against international standards. In 2025, the Company completed a system review and update against the latest revised version of the Good Clinical Practice for Drug Trials (ICH-GCP E6 (R3)) issued by ICH, introducing risk-based quality management concepts, and further strengthening trial compliance and subject rights protection.

The Company has established a complete full-process quality control system, and a professional regulatory and clinical affairs team composed of senior medical device experts carries out work under the overall leadership of the Chief Executive Officer. Based on the original system, the Company formulated documents such as the Standard Operating Procedures for Risk-Based Quality Management of Clinical Trial Projects and the Operating Procedures for Risk-Based Centralized Monitoring, improving the risk identification, evaluation and control processes, and comprehensively enhancing the efficiency and quality level of clinical trial management.

Trial Implementation and Quality Control

The Company conducts clinical trials to scientifically measure the clinical safety and efficacy of medical devices. The core parameters of the trials are strictly set based on the intended use of the products to ensure that the trial design is scientific and reasonable and to achieve a comprehensive evaluation of product performance. During the trial implementation phase, the Company strictly follows the relevant regulations of the NMPA, selects top hospitals with professional qualifications and advanced equipment from the list of officially registered clinical trial institutions as partners, and optimally selects contract research organizations (CRO) with outstanding industry reputation and prominent professional capabilities. We focus on evaluating their qualifications, academic background and project experience, and use a rigorous partner selection mechanism to ensure that the trial process is standardized and data is reliable.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

The Company applies internationally accepted GCP standards throughout all key steps such as trial design, execution monitoring, data collection and result analysis to form a complete closed loop of quality management. We regularly conduct special training on clinical and medical device regulatory systems every year to continuously improve the professional capabilities of the team and provide solid support for the quality of clinical trials. At the same time, we continuously iteratively optimize product design and functions through clinical trial data to ensure that products meet regulatory requirements and improve user experience.

Regulatory Approval and Continuing Improvement

The Company conducts clinical trials for new indications and new products in accordance with specifications to obtain the clinical evidence required for regulatory approvals, and continuously optimizes product design and functions based on clinical trial data to ensure that the products meet regulatory requirements. At the same time, we also continuously iterate on product design and functions, improve product performance and user experience, and further enhance the market competitiveness of the products.

Protection of Rights and Interests of Subjects

The Company continuously strengthens the full-process control of subjects' rights and interests, and introduces multiple targeted protection measures. In terms of the right to be informed, the Company requires research doctors to fully explain the informed consent form to subjects during the recruitment phase, detailing the research purpose, process, potential benefits and risks, to ensure that subjects voluntarily participate on the basis of full understanding. For minor subjects, the Company strictly complies with the Minors Protection Law (《未成年人保護法》) and ethical requirements, adopts a "dual consent" mechanism, and designs a simplified version of informed materials to protect children's right to know. In 2025, the signing rate of informed consent forms for subjects in all clinical trial projects reached 100%, and no forced recruitment or concealment of information occurred.

In terms of privacy and data security, the Company adopts a dual protection mechanism of "de-identification + encrypted storage", assigning a unique anonymous number to each subject to replace their real identity information, and storing core trial data on dedicated servers, setting up three-level access permissions and enabling operation log auditing functions to strictly control data access and operations, effectively protecting the personal privacy of subjects and the security of trial data.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

2. Improving Customer Service Quality

(1) Service Standardization Construction

The Company focuses on ensuring the stability of service quality and realizing the traceability of the entire service process, focuses on the home cognitive rehabilitation service scenario, continuously promotes the construction, implementation and iteration of the service standardization system, and provides professional and efficient service support for patients through clear specifications, strengthened execution and dynamic optimization, building a solid back-end guarantee line for customer service quality, and helping to achieve the core goals of home patients' treatment compliance and training plan completion rate.

Service Process Standardization Construction

Based on the JTBD (Jobs To Be Done) theory, the Company completely disassembles the full service journey of home patients, establishes a four-step standard operating procedure (SOP) of "consultation-delivery-follow-up-repurchase", clarifies the operational specifications, service standards and response timeliness of each step, realizes full-link standardized control from patient consultation access, service delivery, full follow-up to repurchase guidance, eliminates service randomness, and ensures consistent services provided in different service scenarios and by different service personnel. Combined with the medical attributes and home use characteristics of cognitive training products, the Company accurately sets 7 key service touchpoints, formulates standardized service specifications, fully covers core scenarios such as home equipment debugging guidance, training data abnormality warning, training skills Q&A, and quick response to demands, clarifies the service content, operating procedures and quality requirements of each touchpoint, and ensures that services are precisely implemented and rules are followed.

Implementation and Iterative Optimization of Service Standards

Taking the Multi-touchpoint Service Quality Management Specification as the core, the Company embeds service standardization requirements into the entire process, clarifies the unified requirements for service standards of in-hospital, home, and cooperative hospital teams, and ensures seamless connection and consistent standards for services in all links. At the same time, combined with patient feedback, operational data and changes in service scenarios, the Company continuously iterates and optimizes service standards and SOPs, for example, optimizing service touchpoint response timeliness standards and improving knowledge base content specifications based on opinions collected from a three-dimensional survey matrix, continuously enhancing the adaptability and effectiveness of service standardization. Through the continuous improvement of the standardized system, the Company has formed a replicable and promotable home health management SOP, providing solid support for the steady improvement of service quality and a strong guarantee for the consistency of patient experience.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

(2) Focusing on Patient and User Experience

BrainAurora has always been patient-oriented, building a professional service system centered around the full-cycle health management of home rehabilitation. Through refined operations and full-process quality control, we continuously improve service quality and user experience, ensuring the intervention effects of digital therapeutics and patient treatment compliance. Relying on the achievements in evidence-based academic and scientific research in the field of cognitive impairment, as well as the excellent performance of the system and products, the Company's system has been successfully included in the provincial medical insurance reimbursement catalogs of 30 provinces in China. This achievement, while enhancing product accessibility and patients' willingness to use, further optimizes the patient service experience, strengthens the deep linkage between the Company and local medical systems, and allows more patients to enjoy convenient and beneficial medical services.

The Company has established a complete home health management mechanism to coordinate the full-cycle health management of home patients, promote the implementation of core service goals through scientific intervention strategies, fully ensure the compliance rate of patient treatment and the completion rate of staged training plans for digital therapeutics, continuously reduce the dropout rate during the treatment cycle, and form a replicable standard operating procedure for home health management.

Core Goal:

- Ensure the patient treatment compliance rate reaches ≥90%
- Ensure the continuous completion rate of the digital therapeutics staged training plan at key cycle nodes is >85%

In order to comprehensively improve service quality, the Company has built a three-dimensional service management system comprising system guarantee, process coordination, and technical support based on the characteristics of healthcare services, and continuously promotes full-link service experience optimization.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

- **System Guarantee Level**: The Company strictly abides by relevant laws and regulations such as the Law on the Protection of Consumer Rights and Interests (《消費者權益保護法》) and the Regulations on the Prevention and Handling of Medical Disputes (《醫療糾紛預防和處理條例》), formulates the Multi-touchpoint Service Quality Management Specification, clarifies 9 types of service scenario standards such as in-hospital doctor-patient communication, home cognitive training support, and remote follow-up, sets 15 service red lines including key requirements such as privacy protection and informed consent, and at the same time formulates the Graded Response System for Home Patients' Demands, establishing a three-level response mechanism of 2 hours, 24 hours, and 72 hours, giving priority to handling high-risk problems such as cognitive training data abnormalities and equipment failures, ensuring standardized and compliant services, and allowing patients to receive predictable and reliable service experiences.

- **Process Coordination Level**: Taking telephone hotlines and WeChat as the core service main channels, the Company has built a service model combining 7×12 hours manual customer service and intelligent voice diversion, significantly improving the efficiency of patient consultation access. At the same time, the Company strictly implements the responsible person system, requiring dedicated personnel to follow up on the complaints and demands of home patients throughout the process until the problems are resolved in a closed loop, and implementing a case closing countdown mechanism, so that patients can quickly find a coordinating person and solve problems efficiently when encountering problems, effectively enhancing the sense of gain and satisfaction in services.

- **Technical Support Level**: Relying on user behavioral profiles and user lifetime value (LTV) prediction models, the Company implements precise group operations. At the same time, we have built a multi-dimensional knowledge base integrating FAQs, equipment operation guides, and training methods and skills, continuously improving the response efficiency of customer service personnel and shortening the handling time of patient problems and disputes. Through the intelligent early warning mechanism, we identify low-compliance risk groups in advance, trigger the three-level manual intervention process, actively intervene in potential problems during the patient's training process, and shift services from passive response to active care, making them more targeted and effective.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

In order to scientifically measure service effects and patient improvement, the Company has built a three-dimensional service satisfaction survey matrix, comprehensively collecting feedback information through active follow-ups, family collaborative evaluations, and professional cognitive ability scale assessments. Among them, active follow-up relies on the Long Short-Term Memory (LSTM) network model to predict dropout risks and trigger manual intervention, achieving 100% full coverage of patients in training; family collaborative evaluation collects feedback on patients' living abilities through the Activities of Daily Living (ADL) modified scale; professional cognitive assessments adopt the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) to conduct standardized evaluations on patients' cognitive abilities at the initial and stage phases of training. Based on the survey feedback results, the Company expands survey channels to improve survey efficiency and coverage, upgrades the cognitive training emotional adaptation system to reduce patients' training frustration, continuously optimizes service channels and product functions, and effectively improves home training compliance and overall service experience. In 2025, the customer service department effectively handled 1 complaint from home patients, and both the complaint response rate and case closing rate reached 100%, practicing the patient-oriented service concept with actual service results.

(3) Strengthening Data Security Defense Lines

Based on the characteristics of healthcare service data governance, the Company adheres to the core principles of "compliance first, technical support, and full-process protection", builds a data and privacy security management system covering the full service link for home patients, practically guarantees the security of patients' personal information and health data, and builds a foundation of trust for patients to use digital therapeutics services with peace of mind.

Compliance System Construction

The Company strictly complies with the Cybersecurity Law of the PRC (《中華人民共和國網絡安全法》), the Data Security Law of the PRC (《中華人民共和國數據安全法》), the Personal Information Protection Law of the PRC (《中華人民共和國個人信息保護法》), the Guide for Health and Medical Data Security (GB/T 39725-2020) (《GB/T 39725-2020健康醫療數據安全指南》) and other legal and regulatory requirements. Combined with the home cognitive training service scenarios, we have established and improved the data and privacy security management system. At the system level, we have formulated internal norms such as the Information Security Management System, the Data Security Management System, the User Personal Information Security Management System, the Cybersecurity and Data Security Incident Emergency Plan, and the Artificial Intelligence Security System, clarifying the management requirements for the full lifecycle of data collection, storage, transmission, use, and destruction, embedding privacy protection and data compliance requirements into all links of the full service process for home patients, and ensuring that data processing activities are traceable, compliant, and controllable throughout the process. In terms of organizational guarantee, the Company has established an Information Security Management Committee as the highest security management body, and set up a Cybersecurity and Data Compliance Committee and a Cybersecurity and Data Compliance Working Group. This body is headed by the Chief Executive Officer (CEO) as the director and the Chief Security Officer (CSO) as the secretary-general, comprehensively coordinating cybersecurity, data security, and personal information protection, providing solid support for the Company's data security and privacy protection work, and ensuring the implementation of various management system requirements.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Full-link Technical Protection System

The Company has built a multi-level and all-around technical protection system. By strengthening the full lifecycle security protection of data, we implement full-process protection on the personal information and healthcare data of patients, users, and hospitals. We take measures such as data encryption (algorithms like SM4[1], AES256[2]), dynamic de-identification, independent key management, transmission encryption, network isolation, and identity authentication. We have deployed a data security management platform and a data transfer platform to centrally achieve functions such as encryption, de-identification, external distribution, authentication, and auditing, ensuring the security of data collection, transmission, storage, use, and destruction from the source. Relying on the intelligent early warning technical system, the Company triggers a three-level manual intervention process for risk scenarios such as low-compliance populations and abnormal training data, which provides technical support for service accuracy while ensuring data security, realizing a dual guarantee of patient data security and service experience.

Cybersecurity and Data Security Guarantee Capabilities

The Company has formed a professional security team with authoritative qualifications, consisting of professionals holding information security certifications such as Data Protection Officer (DPO), Certified Information Systems Security Professional (CISSP), Certified Information Systems Auditor (CISA), Certified Artificial Intelligence Security Professional (CAISP), and Certified Information Security Professional (CISP), ensuring the effective implementation of security measures.

The Company continuously strengthens its data security guarantee capabilities and builds a professional data security operation and maintenance system. The Company regularly conducts penetration testing and comprehensive risk assessments, covering all business systems and network infrastructure, to timely identify and fix security vulnerabilities. Meanwhile, we routinely organize internal emergency drills, simulating scenarios like data breaches and system attacks, to enhance the emergency response capabilities of the security team. Furthermore, our data security system has passed authoritative certifications, obtaining the Level III Cybersecurity Certification in China, and passing multiple international certifications such as ISO 27001 Information Security Management, ISO 27701 Privacy Information Management, and ISO 20000 IT Service Management internationally, verifying our data security management level with authoritative certifications and providing solid international standard guarantees for patient data security.

---

1 SM4 Algorithm (ShangMi 4): A national standard commercial cryptographic algorithm issued by the State Cryptography Administration of China, used in scenarios such as wireless local area networks. It is a block cipher with both block size and key length of 128 bits.


2 Advanced Encryption Standard (AES): An internationally recognized encryption standard published by the National Institute of Standards and Technology (NIST) of the United States. AES256 specifically refers to the AES algorithm using a 256-bit key, which features extremely high security and is widely adopted by governments and industries worldwide.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT



ISO International Certifications


The Company has obtained the National Level III Cybersecurity Protection Record Certificates for the "66nao Cognitive Digital Therapeutics System" and the "66nao Children's Cognitive Digital Therapeutics System", and conducts level protection assessment work year by year.



Record Certificate for Information System Security Level Protection

The "Cognitive Digital Therapeutics Security Management Platform" independently developed by the Company won the "Pan'an" Excellent Case (Medical Field) at the 2025 Global Digital Economy Conference.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT


荣誉证书

HONORARY CREDENTIAL

数字安全护航计划
CAICT 中国信通院

北京智精灵科技有限公司：

2025年全球数字经济大会数字生态建设专题论坛中，贵公司认知数字疗法安全管理平台案例，在中国信息通信研究院数字安全护航计划组织的2025年度第二期“磐安”优秀案例—医疗领域遴选活动中被评选为优秀案例。

特发此证，以兹鼓励！

中国信息通信研究院
数字安全护航计划
2025年7月

2025 “Pan’an” Excellent Case – Medical Field

The Company actively participates in the formulation of industry standards, plays a leading role in the industry, and spearheaded the compilation and release of the first domestic sets of standards for cognitive digital therapeutics: Cognitive Digital Therapeutics Specification: T/CECCEDA 001-2023 & T/CMS 003-2023 (《認知數字療法規範：T/CECCEDA 001-2023&T/CMS 003-2023》) and Information Security Requirements for Cognitive Digital Therapeutics: T/CECCEDA 007-2023 & T/CMS 009-2023 (《認知數字療法信息安全要求：T/CECCEDA 007-2023&T/CMS 009-2023》). It has also been deeply involved in the formulation of multiple related domestic group standards, including Software Supply Chain Security Requirements T/ISC 0044-2024 (《軟件供應鏈安全要求T/ISC 0044-2024》), Technical Specification for Software Security Development Capability Assessment T/ISC 0042-2024 (《軟件安全開發能力評估技術規範T/ISC 0042 -2024》), Vulnerability Assessment Methods for Embedded Software of Medical Devices – Active Device/Software T/ZMDS 20008-2024 (《醫療器械嵌入式軟件漏洞評估方法有源設備類／軟件類T/ZMDS 20008-2024》), Autonomous and Controllable Cybersecurity Technologies – Interface Specification for Confidential Computing Security Services T/CIIPA 00011-2024 (《自主可控網絡安全技術機密計算安全服務接口規範T/CIIPA 00011 - 2024》), and Autonomous and Controllable Cybersecurity Technologies – Testing Guidelines for Software Autonomous and Controllable Capabilities Based on Cyber Ranges T/CIIPA 00012-2024 (《自主可控網絡安全技術基於網絡靶場的軟件自主可控能力測試指南T/CIIPA 00012 - 2024》).

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

During the information security construction process, BrainAurora has obtained 5 patents and 4 software copyrights:

Patents:

- A data encryption method and system (CN202310882309.7)
- A data generalization method and system (CN202311873672.9)
- A combined security testing method and system (CN202311057138.0)
- Evaluation method and system for data security (CN202211257374.2)
- A method and system for risk management based on digital therapeutics systems (CN202311873956.8)

Software Copyrights:

- "Mobile APP Risk Assessment and Security Management System [Abbreviation: Guanxing] V1.0 Software Copyright Registration No. 12164612"
- "Document Security Management System [Abbreviation: Xinghe] V1.0 Software Copyright Registration No. 12301916"
- "Tianji Data Security Management Platform [Abbreviation: Tianji] V1.0 Software Copyright Registration No. 13179618"
- "Tianxuan Security Management System [Abbreviation: Tianxuan] V1.0 Software Copyright Registration No. 13715988"

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

User Privacy Management

The Company strictly follows the "minimum and necessary" principle to collect patient information, only obtaining necessary information required for digital therapeutics intervention, preventing excessive collection. In the privacy policy, we clearly inform the purpose, scope of use, and user rights of information collection, and ensure that patients fully understand and voluntarily authorize through initial privacy pop-ups, page notifications, etc. At the same time, we guarantee the personal information rights of patients, supporting patients to query, correct, delete personal information, and withdraw information use authorization, strictly prohibiting the disclosure of sensitive information such as personal biometric information, race, and medical record numbers. For service scenarios such as follow-up and repurchase for home patients, the Company refines privacy protection operating procedures, clarifies user privacy protection mechanisms and emergency response procedures, and uses data de-identification technology to automatically shield sensitive information such as patients' ID numbers and contact details, ensuring that data usage is compliant and transparent, effectively safeguarding patient information security and legitimate rights and interests.

The Company implements differentiated management based on data sensitivity by establishing a data classification and grading management system, and executes data review and approval procedures. Business contracts and confidentiality agreements are signed for all collaborations, and project personnel and staff must sign confidentiality agreements upon joining. At the same time, the Company will carry out personal information protection impact assessments to ensure that data processing activities comply with the requirements of regulations such as the Cybersecurity Law (《網絡安全法》), the Data Security Law (《數據安全法》), and the Personal Information Protection Law (《個人信息保護法》).

Strengthening Information Security and Privacy Protection Awareness

Employee training is an important measure for BrainAurora to enhance employees' awareness of information security and privacy protection. The Company has established a complete information security and privacy protection training system. New employees must complete information security training courses and pass the exams in the month they join, guiding them to consciously abide by security regulations in combination with actual work scenarios. We conduct differentiated special training for different positions such as technology R&D and business operations, such as data security training and AI security risk training, to ensure that the training content accurately matches position risks. In addition, through the internal enterprise learning platform, enterprise WeChat groups, and all-staff emails, the Company regularly pushes spam warnings, security training documents, and video teaching materials, simultaneously popularizing knowledge on personal information protection, user privacy authorization management, sensitive data de-identification, etc. We are committed to helping employees keep abreast of the latest security trends and develop good operational habits through continuous knowledge dissemination.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

The Company strictly implements patient privacy protection and the "minimum and necessary" data use principle by continuously upgrading and iterating the data security management platform, strengthening the automated discovery and classification and grading capabilities of data assets. As of the end of 2025, the Company has not experienced any major cybersecurity, data security, or personal information disclosure incidents, nor has it been investigated or penalized by regulatory authorities such as cyberspace, public security, cybersecurity, and industry and information technology departments.

(4) Responsible Marketing

Based on the characteristics of the healthcare industry, the Company adheres to the marketing philosophy of "compliance first, authenticity and transparency, and integrity in business", strictly abides by relevant laws, regulations and industry norms, and builds a three-in-one responsible marketing system of "system control – special governance – capability enhancement". We standardize the marketing behavior in the entire process, put an end to non-compliant propaganda, practically safeguard the rights and interests of patients, and establish a professional and trustworthy brand image.

The Company has established a comprehensive institutional system and special governance mechanism in terms of marketing compliance, strictly abiding by laws and regulations such as the Advertisement Law (《廣告法》), the Medical Advertising Management Measures (《醫療廣告管理辦法》), and the Personal Information Protection Law (《個人信息保護法》), and accordingly formulated a series of internal specifications such as the Marketing Full Cycle Management Specification 1.0 and the Marketing Specification and Quality Inspection Manual for Home Patients. With modular design, we cover four core scenarios: market research, academic promotion, business contracting, and home patient services. We have also set up 12 compliance review nodes in key links, embedding compliance requirements into the entire marketing process. At the special governance level, the Company has established a dual red-line mechanism centered on "propaganda content control" and "user privacy protection", strictly prohibiting any exaggerated or false propaganda, and ensuring that all content is true, accurate, and compliant.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

3. R&D and Innovation

The Company has always regarded R&D and innovation as the core driving force for development, focusing on the field of cognitive impairment digital therapeutics. With the core strategy of "empowering healthcare with technology and guarding health with innovation", we continue to increase R&D investment and improve the R&D system and innovation mechanisms. At the same time, we keep up with frontier technology trends in the industry such as Artificial Intelligence (AI), Virtual Reality (VR), and big data, deepen the integrated application of VR technology and AI technology in the medical field, promote the iterative upgrading of digital therapeutics products and core technological breakthroughs, and help improve the precision and effectiveness of cognitive impairment diagnosis and treatment. To strengthen R&D capabilities, the Company has built a professional R&D team and improved its technical infrastructure. At the same time, it has built joint laboratories with universities to focus on breakthroughs in key core technologies of assessment and intervention, forming an innovative development model of "investment guarantee, talent support, and industry-university-research synergy".

(1) Digital Science and Technology Innovation

BrainAurora deeply cultivates digital technology innovation, promotes the deep integration of cutting-edge technologies and cognitive impairment digital therapeutics, and creates diversified innovative solutions to empower the high-quality development of the industry with innovative achievements. The Company is committed to promoting the development of cognitive impairment digital therapeutics using cutting-edge digital technologies. By integrating innovative technologies such as AI and VR, it has developed a series of personalized assessment and intervention solutions with clinical value. Currently, it has launched innovative digital therapeutics products in multiple fields such as mental health, children's health, and elderly health, such as 66nao® cognitive digital therapeutics (cognitive training), VR eye movement cognitive assessment, AI intelligent scales, and soul island Aurora.

In terms of technological innovation applications, we fully integrate digital technologies such as AI, VR, and big data into product R&D and clinical applications. Among them, our independently developed medical large model BrainAuGPT adopts a training method based on GBR (Graph-based Bundle Recommendation) second-order knowledge representation, and its task combination recommendation method has obtained national invention patent authorization. Supported by the medical large model, the virtual human intelligent assessment system realizes a comprehensive upgrade, accurately capturing patients' emotional changes and conducting empathetic interactions, improving the accuracy of intent understanding. Meanwhile, the Company successfully released the intelligent medical large model all-in-one machine BrainAu Onebox M1, further improving the precision and intelligence level of digital therapeutics. The dyslexia auxiliary training we developed provides personalized treatment plans by analyzing patients' training data with big data, effectively improving training effects and patient compliance. The multi-language version of cognitive digital therapeutics, independently developed by the Company simultaneously, supports Mandarin, English, and Cantonese, meeting the usage needs of patients in different regions. In the clinical application field, the Company has made major breakthroughs in the direction of digital-drug combination for children's Attention Deficit Hyperactivity Disorder (ADHD), filling the gap in evidence-based research of ADHD digital therapeutics in China, and opening up a new path for the innovative development of digital therapeutics.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

In terms of team building, the Company continues to increase R&D investment, strengthen the construction of the R&D talent team, improve the talent introduction and cultivation and innovation mechanisms, and build joint laboratories with universities to focus on breaking through key technologies related to assessment and intervention. Currently, we have built a R&D team composed of 131 professionals, including 27 with master's degrees, 3 with doctorate degrees, and multiple professional technical backbones. Through systematic cultivation and regular technical exchanges, we continuously improve the overall professional quality and technological innovation capability of the R&D team.

During the reporting period, the Company achieved remarkable results in the field of science and technology innovation, and its core technologies and products won multiple industry awards.

- "Personalized Intervention Technology Based on Cognitive Deep Reasoning Large Models" was selected as a "Typical Case of AI Empowering Industry Development" at the 2025 Global Digital Economy Conference, the "2025 Annual Benchmark Case of Digital Intelligence Innovation" at the Beijing-Tianjin-Hebei CIO Digital Intelligence Innovation Conference, and the "AI Solution Recommended by the China Association of Small and Medium Enterprises" at the 2025 World Artificial Intelligence Conference
- "Quantitative Diagnosis and Treatment Full-Course Technology System for Depression" won the Beijing Science and Technology Award
- "66nao Cognitive Impairment Digital Therapeutics" won the AI Scenario Benchmark Case Award at the "Fourth China Data Factor Summit Forum"

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

[Case: BrainAurora's innovative achievement, cognitive impairment digital therapeutics, was evaluated in the "Beijing New Technology, New Product (New Service)" List]

In 2025, BrainAurora's cognitive impairment digital therapeutics was successfully selected into the 20th batch of the 'Beijing New Technology, New Product (New Service)' list, receiving authoritative recognition for its advanced technology, clinical reliability, and market application value. Relying on the cognitive function norm of 800,000 people to achieve accurate assessment, the product uses multi-modal digital intervention technology to improve training effectiveness, and builds an integrated intelligent diagnosis and treatment platform covering screening, assessment, and intervention, which can be flexibly adapted to multiple application scenarios in homes and hospitals. The Company has carried out clinical research with thousands of medical institutions such as Xuanwu Hospital of Capital Medical University, jointly published a number of high-impact academic achievements, promoted the formation of multiple industry guidelines and expert consensuses, and related digital therapeutics have been promoted in hundreds of medical institutions nationwide, cumulatively serving patients over 20 million times. This recognition is not only a high affirmation of the Company's technological innovation and clinical transformation capabilities, but also sets a benchmark for the popularization of technology and the high-quality development of the industry in the field of cognitive impairment prevention and treatment.


北京市新技术新产品新服务
证　书

单位名称：北京智精灵科技有限公司
新服务名称：六六脑认知障碍数字疗法

证书编号：XFW2024SWYY1374
发证日期：2025年7月
有效期：3年

批准机关：

Beijing New Technology, New Product, New Service Certificate

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

[Case: Technological achievements win international recognition, large model research paper selected for top international conference NAACL 2025]

BrainAurora continues to uphold the concept of "reshaping cognition with technology and letting life bloom with brilliance." Aiming at the widespread "hallucination" output problem in large language models (LLMs) in recent years, the technical team carried out a special breakthrough and proposed an innovative method of cross-layer Entropy eNhanced Decoding (END). This method effectively mitigates hallucination bias without additional training of model parameters, balancing content authenticity, information richness, and Q&A accuracy. The related academic paper research result, Improve Decoding Factuality by Token-wise Cross Layer Entropy of Large Language Models, was successfully included in the North American Chapter of the Association for Computational Linguistics (NAACL), one of the top three international conferences in the field of natural language processing, highlighting the Company's solid underlying algorithm R&D strength. BrainAurora's technical team continues to cultivate foundational AI technological innovation, focuses on the safe and reliable application of medical large models, and constantly breaks through key bottlenecks in the industry, building a solid technological foundation for the steady implementation of cognitive impairment digital therapeutics.




Figure 2: **(1)** The left figure illustrates the predicting distribution differences, measure by KL-divergence, between the final layer and even-numbered early layers of the whole output sentence. Row names are indices of the early layer used for contrasting and column names are decoded tokens at each generation step. **(2)** The right figure illustrates the predicting probabilities of high probability candidate tokens among higher layers at the first generation step of token '*_Sun*'. Row names are indices of the layer and column names are candidate tokens.

Paper: Improve Decoding Factuality by Token-wise Cross Layer Entropy of Large Language Models

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

(2) Industry Empowerment

As an innovative leader in the field of cognitive impairment digital therapeutics, we are always actively involved in the construction of the industry ecosystem. We have assisted over 206 hospitals nationwide in successfully establishing cognitive centers, driving the standardized development of the digital therapeutics market. At the same time, through academic exchanges, technology demonstrations, and other forms, we bring innovative achievements to benefit more patients. In 2025, the Company's multiple digital technology innovation achievements gained authoritative industry recognition, highlighting the Company's core strength in the field of digital technology innovation.

[Case: Jointly initiated a special plan with People's Health to empower the high-quality development of cognitive impairment specialties]

In 2025, relying on the "Cognitive Digital Health Specialty Service Plan" jointly initiated with People's Daily Online • People's Health, the Company extended a series of activities for the high-quality development of public hospitals. It focused on holding symposiums on the high-quality development of cognitive impairment specialties, linking national public hospitals and pharmaceutical industry enterprise experts to gather and discuss industry development. The activity aimed to deepen the standardized construction of cognitive impairment specialties through a series of solid and pragmatic efforts, promote the scenario exploration of the cognitive digital therapeutics technology solutions independently developed by the Company, and explore a high-quality development path for cognitive impairment specialties that conforms to the current status of China's medical system. Relying on its full-stack AI capabilities and advantages in cognitive digital technology, the Company promoted the iterative optimization of cognitive assessment and intervention tools, assisted in the transformation of scientific research results into clinical applications, empowered the high-quality development of the industry with technological innovation, and demonstrated the enterprise's industry responsibility and leading role in the field of cognitive impairment prevention and treatment.





"Cognitive Digital Health Specialty Service Plan" Activity Scene

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

[Case: Deeply linking with the National Health Commission, empowering the capability enhancement of primary-level cognitive impairment diagnosis and treatment with digital technology]

In 2025, BrainAurora actively devoted to the Healthy China strategy, closely following the National Health Commission's work deployment on cognitive impairment prevention and treatment, and carrying out a series of public welfare actions in the field of cognitive impairment prevention and treatment, achieving particularly remarkable results in medical inclusivity. To solve the pain points of lacking primary-level cognitive impairment diagnosis and treatment resources, a shortage of professional talents, and a low level of standardization in China, the Company deeply participated in the "Cognitive Impairment Disease Specialty Capacity Building" talent training project of the National Health Commission. Relying on its independently developed cognitive digital therapeutics technology, it is closely linked with government agencies and primary-level medical institutions, building an all-around cooperation model of "technical support + talent cultivation + diagnosis and treatment empowerment".

[Case: Joining hands with Beijing Hospital of Traditional Chinese Medicine to co-build the "AI + TCM" cognitive impairment intervention platform, innovating a new path for integrated traditional Chinese and Western medicine prevention and treatment]

In July 2025, supported by the Beijing Municipal Commission of Science and Technology, BrainAurora and the Beijing Hospital of Traditional Chinese Medicine affiliated with Capital Medical University jointly launched the "Digital Therapeutics + TCM Brain Health Intervention Platform" project, and jointly unveiled the cognitive center to promote the deep integration of artificial intelligence and traditional Chinese medicine. The project carried out clinical research around directions such as electroacupuncture combined with digital therapeutics, and TCM prescription collaborative intervention. It combined traditional Chinese medicine characteristic therapies such as acupuncture, prescriptions, and five-element music with AI cognitive assessment and precise digital intervention to build a cognitive impairment diagnosis and treatment system featuring traditional Chinese and Western medicine collaboration. Academician Tian Jinzhou, the hospital expert team, and the Company were deeply involved in the scheme design. Relying on the technical and clinical advantages of both parties, they created an innovative diagnosis and treatment model integrating screening, assessment, and intervention, providing personalized and scientific treatment plans for patients with cognitive impairment, and helping the "Healthy China" construction and TCM digital innovation development.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT





“Digital Therapeutics + TCM Brain Health Intervention Platform Construction and Promotion” Project Launch Meeting

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

[Case: Cooperating with Anding Hospital to launch the R&D and clinical application project of a comprehensive digital therapeutics system for emotional intervention based on AI]

In June 2025, under the special support of the "AI + Health Collaborative Innovation Cultivation" of the Beijing Municipal Commission of Science and Technology, BrainAurora, as the leading technical enterprise, united with Beijing Anding Hospital affiliated with Capital Medical University and multiple scientific research and medical institutions to launch the R&D and clinical application project of a comprehensive digital therapeutics system for emotional intervention based on AI. The project closely followed the "Healthy China" strategy, focusing on the diagnosis and treatment of pain points of mental disorders combined with cognitive impairment. Combining Anding Hospital's rich clinical diagnosis and treatment experience and BrainAurora's multi-modal AI technology advantages, it builds an integrated digital diagnosis and treatment platform covering the whole process of screening, intervention, and follow-up. The platform integrates perception technologies such as eye tracking and voice analysis with deep learning algorithms, optimizes intervention pathways combined with mature evidence-based product practices, and at the same time, the project carries out GCP special training, strictly adhering to ethical and compliance requirements. In the future, both parties plan to link multiple diagnosis and treatment centers to deepen clinical verification and pathway standardization construction, promote the transformation and implementation of medical devices, and with the integrated innovation of "AI + Mental Healthcare", provide precise and intelligent digital guardianship for populations with emotional-cognitive comorbidities, helping the upgrading of the mental and psychological health service system.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT





Launch Meeting for "R&D and Demonstration Application of Cognitive Impairment Disease Digital Therapeutics Products"

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

(3) Intellectual Property Protection

The Company strictly complies with the Patent Law of the PRC (《中華人民共和國專利法》), the Trademark Law of the PRC (《中華人民共和國商標法》), and other relevant laws and regulations, building a complete intellectual property protection system to provide a solid guarantee for R&D and innovation achievements.

- **System Level**: The Company formulates a complete intellectual property management system, clarifies specific requirements for intellectual property protection, and hires professional teams to provide legal support, ensuring that intellectual property protection work is legally compliant and steadily advanced.

- **Patent Management**: The Company establishes and improves the patent management system, conducts comprehensive infringement risk analysis, achieves full-process control of intellectual property from application and review to usage through standardized processes. Simultaneously, it builds an intellectual property database to realize real-time data updating, enhancing patent search and management efficiency.

- **Trademark Management**: The Company establishes a strict trademark management system, standardizes links such as trademark registration and use, ensures that trademark management complies with legal and regulatory requirements, and leverages professional intellectual property services to effectively avoid infringement risks, practically protecting R&D achievements in the digital therapeutics field.

The Company attaches great importance to cultivating awareness of intellectual property protection, integrating it deeply from R&D to sales. We conduct normalized special training for marketing teams, core technical personnel, and R&D teams, focusing on explaining the key protection points for patents, trademarks, and software copyrights, guiding employees to standardize the use of intellectual property such as patents and trademarks, continuously enhancing the awareness of intellectual property risk prevention among all employees, building a solid compliance guarantee for technological innovation achievements, and eliminating infringement behaviors from the source.

As of the end of 2025, the Company has cumulatively obtained 72 authorized patents, registered 85 software copyrights, and 188 trademarks. No intellectual property litigation cases have occurred, providing a strong guarantee for the continuous advancement of R&D and innovation work.

III. GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES

1. Strengthening Emission Control

BrainAurora strictly follows the Law of the People's Republic of China on the Prevention and Control of Atmospheric Pollution (《中華人民共和國大氣污染防治法》), the Law of the People's Republic of China on the Prevention and Control of Water Pollution(《中華人民共和國水污染防治法》), the Law of the People's Republic of China on the Prevention and Control of Environmental Pollution by Solid Wastes (《中華人民共和國固體廢物污染環境防治法》)and other relevant laws and regulations, practically prevents its emissions from polluting the environment, requires all business segments to proactively identify and control environmental risks, and makes maximum efforts to reduce the potential impact on the ecological environment and natural resources during the operational process.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

As a company with digital healthcare as its core business, BrainAurora's operational model is R&D-oriented and does not involve physical manufacturing activities. Therefore, the amount of waste gases and greenhouse gases emitted by the Company, pollutants discharged into water and land, as well as hazardous and non-hazardous wastes generated is relatively limited, having a minor impact on the environment. The non-hazardous wastes generated by the Company mainly come from daily office work, such as office garbage and consumables wastes; the hazardous wastes are mainly discarded toner cartridges and ink cartridges of office printing equipment.

(1) Non-hazardous Wastes

BrainAurora always adheres to the concept of sustainable development, effectively implements the waste management system, ensures the standardization of management work, actively explores new methods of waste resource recycling and utilization, and reduces the risk of environmental pollution. We establish and implement a standardized waste disposal mechanism. Office garbage is uniformly transported by the property management to designated garbage recycling points for classification and processing, and scrapped electronic equipment is handed over to professional suppliers for recycling and reasonable disposal. At the same time, we actively respond to the national garbage classification policy, set up classified garbage bins in office areas, carry out publicity and guidance, encourage employees to actively participate in garbage classification, and improve the level of resource recycling and utilization.

(2) Hazardous Wastes

For hazardous wastes such as toner cartridges and ink cartridges generated in the office, the Company hands them over to professional third-party companies for recycling or disposal, ensuring the safe management of hazardous wastes.

(3) Waste Water

The Company's waste water mainly comes from sewage generated in daily office work. According to national and local operational requirements, we transport the sewage through dedicated pipeline systems to municipal sewage treatment plants for treatment before discharge.

During the year, BrainAurora continued to implement garbage classification and electronic waste harmless treatment measures, steadily advancing the process of waste reduction management goals.

Goal type	Goal content	Completion progress
Waste reduction	Implement waste separation in all office areas of BrainAurora every year; realize 100% safe treatment of e-waste generated in all office areas	The goal for 2025 has been achieved

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

During the reporting period, the key performance data of the Company's emissions are shown in the table below. According to the principle of materiality, the scope of key environmental performance indicators covers the Beijing office, Changsha office and Hong Kong office of the Company.

Indicator[3]		Data in 2025	Data in 2024
Waste gas[4]	**Emissions of nitrogen oxides** (kg)	**130.27**	60.47
	Emissions of sulfur oxides (kg)	**0.28**	0.10
	Emissions of Particulate matter (kg)	**12.48**	5.79
Waste	**Emissions of hazardous waste**[5] (ton)	**0.0375**	0.044
	Emissions of per-capita hazardous waste (kg/person)	**0.219**	0.277
	Emissions of non-hazardous waste[6] (ton)	**6.2**	0.6
	Emissions of per-capita non-hazardous waste (kg/person)	**36.26**	3.774

2. Optimizing the Resource Utilization

BrainAurora strictly follows the Law of the People's Republic of China on Environmental Protection (《中華人民共和國環境保護法》), the Law of the People's Republic of China on Conserving Energy (《中華人民共和國節約能源法》) and other laws and regulations, and continuously executes the Management Measures for Administrative Cost Reduction Control. Through implementing a series of energy-saving and consumption-reducing measures such as saving electricity, saving water, and green office, the Company continuously optimizes resource allocation methods and deepens green and low-carbon requirements.

(1) Saving Electricity

The Company encourages the prior use of natural light in the office, replaces high-energy-consuming lamps with energy-saving lamps, and advocates employees to turn off lights, air conditioners, computers, and display screens in meeting rooms in a timely manner after getting off work or at the end of a meeting, pay attention to the electricity usage in various areas, and proactively turn off electronic devices that are not in use to reduce unnecessary electricity consumption. We establish a responsibility system for saving electricity. During working hours, the users of equipment, the administrative department, and the meeting initiators are respectively responsible for the electricity management of the corresponding areas. In non-working hours, the "final leave inspection system" is implemented, and a corresponding accountability mechanism is established to effectively implement energy-saving measures.

---

3 During the year, emission data coverage has been expanded to include the Hong Kong office. The emissions of per-capita hazardous waste and emissions of per-capita non-hazardous waste of the Company are calculated based on the total number of full-time employees.

4 The company's waste gas emissions originate from the operation of official vehicles, and the calculation method refers to the ESG Reporting Guide for Environmental Key Performance Indicators issued by the Hong Kong Stock Exchange. During the year, the usage frequency of official vehicles increased significantly due to business expansion. Accordingly, waste gas indicators (including emissions of nitrogen oxides, emissions of sulfur oxides and emissions of particulate matter) changed materially compared with 2024.

5 Hazardous wastes involved in the Company's operations mainly include waste toner cartridges and ink cartridges from office printing equipment.

6 Non-hazardous wastes involved in the Company's operations mainly include office waste and discarded office consumables. During the year, the usage of packaging materials increased due to office relocation and equipment procurement. Accordingly, the total emissions of non-hazardous waste and per-capita emissions of non-hazardous waste changed materially compared with 2024.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

In terms of air conditioning usage, the Company implements tiered temperature control, reasonably setting indoor temperature to reduce electricity consumption. The Company stipulates that in summer, the cooling function is activated only when the indoor temperature exceeds 26°C and the temperature is set no lower than 24°C; in winter, the heating function is activated only when the temperature falls below 18°C and the temperature is set no higher than 20°C. The Company arranges professional personnel to clean air conditioner filters regularly every year to ensure equipment running efficiency. Furthermore, the Company requires employees to close doors and windows while using the air conditioner, eliminating energy waste.

(2) Saving Water

We strictly comply with the Water Law of the People's Republic of China (《中華人民共和國水法》), the Law of the People's Republic of China on Prevention and Control of Water Pollution (《中華人民共和國水污染防治法》), the Regulations on Water Conservation of the People's Republic of China (《中華人民共和國節約用水條例》), and other national laws, regulations, and policies, taking a series of practical water resource management measures. By strengthening the daily maintenance of water-using equipment and promoting the use of water-saving faucets, we eliminate water resource waste from the source. At the same time, the Company pays attention to cultivating employees' awareness of water conservation, posts water-saving signs in prominent locations, and regularly conducts employee water-saving training to help employees gradually develop good habits of saving water.

(3) Green Office

The Company comprehensively promotes green office practices and establishes a closed-loop mechanism of "source control – process management – terminal reduction". In the document circulation process, we prioritize electronic methods; when printing is necessary, it must be printed on double sides and carefully proofread in advance to avoid repetitive printing. Office supplies implement a system of "exchanging old for new, receiving on demand", establishing complete usage ledgers; new employees apply as needed, and upon resignation, they return the remaining items, and are advocated to properly store and extend the life of the supplies. Disposable consumables are strictly controlled, employees must bring their own water cups and tableware, and are advocated to save the use of consumables such as toilet paper.

During the year, BrainAurora successfully achieved its resource utilization and management goals. With the continuous implementation of energy conservation and emission reduction measures, per-capita electricity consumption and per-capita water consumption significantly decreased compared with the previous year, and the relevant goals were realized as scheduled.

Goal type	Goal content	Completion progress
Energy management	Reduce per-capita electricity consumption by 5% by 2026 compared with that in 2024.	Reduce per-capita electricity consumption by 5.3% in 2025 compared with that in 2024.
Water resource	Reduce per-capita water consumption by 5% by 2026 compared with that in 2024.	Reduce per-capita water consumption by 21% in 2025 compared with that in 2024.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

During the reporting period, the key performance data of the Company's resource usage are shown in the table below. According to the principle of materiality, the scope of key environmental performance indicators covers the Beijing office, Changsha office and Hong Kong office of the Company.

Indicator[7]	Data in 2025	Data in 2024
Total consumption of comprehensive energy (MWh)[8]	**359.99**	263.95
Per-capita energy consumption (MWh/person)	**2.11**	1.66
Direct energy consumption (MWh)[9]	**168.56**	59.72
In which: oil consumption of official vehicles	**168.56**	59.72
Indirect energy consumption (MWh)	**191.43**	204.23
In which: purchased electricity	**191.43**	204.23
Daily water consumption (ton)	**2,106**	2,377
Per-capita daily water consumption (ton/person)	**12.32**	14.95

3. Addressing Climate Change

BrainAurora attaches great importance to work related to addressing climate change, and proactively identifies and evaluates the potential impact of climate change risks and opportunities on the Company's business. We fully understand the potential social and environmental impacts of our business operations, continuously improve our climate risk strategy system, and actively respond to the national dual carbon targets. During the year, we comprehensively disclosed the Company's efforts in climate-related risk management and response measures across four areas: governance, strategy, risk management, and metrics and targets.

(1) Governance

We regard climate change topics as a core component of the enterprise's sustainable development strategy, and have established a clear and tiered climate-related governance structure to ensure that the management of climate-related risks and opportunities is integrated into daily operations.

---

7 The Company's daily operations do not involve manufacturing activities, therefore packaging data is not applicable to the Company. During the year, resource usage data coverage has been expanded to include the Hong Kong office. The per-capita energy consumption and per-capita daily water consumption of the Company are calculated based on the total number of full-time employees.

8 Total energy consumption is calculated based on electricity consumption and relevant conversion factors provided in the General Principles for Calculation of Comprehensive Energy Consumption (《綜合能耗計算通則》) (GB/T 2589-2020), a national standard of the People's Republic of China.

9 During the year, the usage frequency of official vehicles increased significantly due to business expansion. Accordingly, direct energy consumption, oil consumption of official vehicles and total consumption of comprehensive energy changed materially compared with 2024.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

The Board of Directors, as the highest responsible body for the Company's climate-related governance, assumes oversight and decision-making responsibilities. The Board regularly reviews the Company's climate-related performance, evaluates the impact of climate change on business strategy and long-term resilience, and oversees the effectiveness of the climate risk management system to ensure decisions align with the Company's overall sustainable development goals.

The ESG Committee assists the Board in formulating climate-related strategies and policies, is responsible for assessing climate-related opportunities and risks, incorporates climate topics into the Company's ESG strategy framework, guides the establishment of a sound climate risk management process and internal monitoring mechanism, and ensures that relevant policies and disclosures comply with the Hong Kong Stock Exchange's ESG Reporting Code and regulatory requirements.

The ESG Working Group is responsible for the execution and implementation of climate-related work. The working group is composed of core personnel from various business departments, undertaking specific functions such as climate risk identification, scenario analysis, data collection, and advancing emission reduction actions. Through cross-departmental coordination, it ensures the effective implementation of climate-related initiatives across business lines, and regularly reports progress to the Board and the ESG Committee.

(2) Strategy

At the strategic level, the Company adopts the SSP1-2.6, SSP2-4.5, and SSP5-8.5 scenarios[10] of the Intergovernmental Panel on Climate Change (IPCC) as physical scenarios, and adopts the Net Zero Emissions Scenario (NZE) and the Announced Pledges Scenario (APS)[11] of the International Energy Agency (IEA) as transition scenarios for stress testing related risks and analyzing climate resilience. At the same time, the Company comprehensively considers the national dual carbon strategic goals and its own development plans, specifies short-, medium-, and long-term timeframes, accordingly evaluates climate change risks and opportunities, and takes targeted measures to enhance the Company's capability to address climate change.

Short, Medium, and Long-term Timeframes

2025 to 2030	2031 to 2035	2036 to 2050
Short-term	Medium-term	Long-term

10 SSP scenarios describe emission levels and climate change trends under different socioeconomic development pathways: SSP1-2.6 represents a scenario of sustainable development and low emissions; SSP2-4.5 represents a scenario of medium emissions with uneven policy implementation; SSP5-8.5 represents a high-emission scenario with continued reliance on fossil fuels.

11 The IEA Transition Scenarios are used to simulate the global energy structure and policy pathways: NZE is an ambitious emission reduction scenario for the world to achieve net-zero emissions by 2050; APS is a policy scenario in which countries fulfill their announced climate and energy pledges as scheduled.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

During the year, based on the global climate change situation, leading industry practices, and internal and external discussions, we continuously assessed the potential climate physical risks, transition risks, and climate opportunities within BrainAurora's operational scope and value chain.

Risk Category	Timeframe of Significant Impact	Impact on the Company's Value Chain	Risk Description	Countermeasures
Transition risks				
Policies and laws risks	Short, Medium-term	Own operations	• The government and regulatory authorities may implement more stringent environmental laws, regulations and policies in the future, which may increase the Company's environmental compliance costs.	• Identify the sources of carbon emissions during operations and ensure the accuracy and timeliness of carbon emission data; • Take climate change as an important topic, actively communicate with shareholders, and provide relevant training for all employees.
Market risks	Short, Medium-term	Capital end and investors, Own operations, Market end	• Increasingly stringent environmental protection policies (including waste emission regulations) and rising prices of basic resources (such as energy and water resources) have led to higher overall operating costs for the Company.	• Improve energy efficiency by using energy-saving lamps and induction faucets, etc.
Reputation risks	Medium, Long-term	Capital end and investors, Own operations, Market end	• With the transition to a low-carbon economy, stakeholders are paying more and more attention to the Company's performance in green and low-carbon development and addressing climate change. If there is a discrepancy in expectations, it may affect the Company's reputation and image.	• Accelerate the Company's low-carbon transition; • Establish a green and low-carbon corporate image, such as advocating employees to take public transportation for travel, reducing vehicle utilization, etc.; • Actively formulate and disclose carbon reduction targets and corresponding emission reduction measures.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Risk Category	Timeframe of Significant Impact	Impact on the Company's Value Chain	Risk Description	Countermeasures
Physical risks				
Acute risks	Short-term	Own operations, Service delivery	• The frequency of natural disasters such as floods, heavy rains and snow, and typhoons has increased, which may cause disruptions in the medical equipment supply chain and abnormal power supply, affecting patient compliance (power outages make equipment unusable) and causing property losses and other adverse situations, thereby threatening the normal operation of the Company.	• Pay close attention to the extreme weather event forecasts provided by the climate department, establish emergency plans, including emergency plans for major disaster weather and medical supplies shortage, etc., and access the National Meteorological Centre API to achieve 72-hour accurate warning; • Based on geographic location and health data, dynamically push personalized protection suggestions to patients; • Pay close attention to the physical health of employees and develop flexible work methods.
Chronic risks	Medium, Long-term	Own operations	• The increase in high temperature weather leads to continuous high temperatures, which may cause physical discomfort to employees and reduce work efficiency; • The Company's operating costs increase, such as increased electricity consumption and logistics costs, etc.	

Opportunity Category	Timeframe of Significant Impact	Impact on the Company's Value Chain	Opportunity Description	Countermeasures
Products and services	Medium, Long-term	Product competitiveness, Market end	• As global climate change intensifies, the symptoms of patients with cognitive impairment may be aggravated; or offline hospital visits may be hindered, significantly increasing patients' demand for remote, home-based digital rehabilitation.	• Conduct innovative research, develop intervention options to deal with climate-sensitive symptoms; develop climate-adaptive digital medical products.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Climate Resilience

BrainAurora systematically incorporates climate change factors into the Company's long-term development strategy. We use SSP5-8.5 (high emission scenario) and the Net Zero Emissions scenario (NZE) for stress testing to evaluate the business's adaptability under different climate environments. We identified that the high-risk segment is primarily the impact of extreme weather (such as typhoons and heavy rains) on the continuity of medical services. In terms of physical resilience, the Company focuses on the potential threats posed by extreme weather (such as typhoons, heavy rains, etc.) to the continuity of medical services. By accessing precise meteorological early warning systems and formulating comprehensive emergency plans for the digital platform, we can ensure a rapid response when disasters occur, maintain the stability of remote medical services, and ensure that patients' intervention treatments are not restricted by physical environments. In terms of transition resilience, the Company actively responds to the national "dual carbon" strategy, and by improving resource utilization efficiency in office locations and data processing processes, it proactively lays out low-carbon operational models, thereby effectively resisting the risk of cost fluctuations brought about by the tightening of future environmental protection policies. By specifying short-, medium-, and long-term timeframes, we continuously optimize resource allocation to ensure the Company maintains stable business growth and social value creation capability amid climate fluctuations.

Financial Impact


During the year, BrainAurora identified the following risks and opportunities with high financial materiality:

Risk and Opportunity Type	Impact on Current Finances	Change Trend of Countermeasure Impact on the Company's Finances in the Short-, Medium-, and Long-term
Physical risk – Extreme weather	Extreme weather may lead to short-term operational interruptions in some office or service support links, or incur additional asset maintenance costs, causing fluctuations in current operating costs.	In the short term, reduce direct losses by optimizing emergency plans; In the long-term, as the risk-resistance capability of the remote service system improves, related financial losses will be kept under at a controlled level.
Transition risk – Low-carbon technology transition	To meet regulatory requirements and the market expectation for green digital products, the Company has certain investment needs in procuring high-efficiency equipment and upgrading digital technologies.	Related expenditures are expected to be smoothly released in the short- and medium-term along with project progress. Continuous technology tracking helps to guarantee the long-term competitiveness and revenue stability of digital products under the low-carbon trend.
Opportunity – Digital medical products and services	As the impact of climate change on public health deepens, market demand for remote, home-based digital rehabilitation solutions grows significantly, bringing opportunities for business expansion for the Company.	By enhancing the scenario adaptability of its products, the Company is expected to attract more attention from ESG-preference capital in the medium- to long-term, thereby optimizing financing costs and achieving further enhancement of overall business value.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

(3) Risk Management

We have established a systematic climate risk management and continuous assessment mechanism to regularly review and update the climate risk and opportunity list. Through a standardized risk assessment process, we evaluate the degree of impact of identified climate-related risks and opportunities, formulate targeted response measures, and form a closed-loop climate risk management system of "identification – assessment – monitoring – response".



- Identification: Based on the Company's actual production and operations, combined with industry trends, domestic and foreign policy environments, and advanced practice benchmarking, systematically identify climate risks and opportunities, and form a list.
- Assessment: Combined with operating conditions, evaluate the applicability and materiality of risks and opportunities, conduct comprehensive research from dimensions such as probability of occurrence, business impact, financial impact, and reputational impact, and determine risk levels and substantive opportunities.
- Monitoring: Continuously communicate with stakeholders, regularly review and update assessment results, ensuring that risks, opportunities, and countermeasures match the Company's actual situation.
- Response: Formulate and implement response plans based on the identification and assessment results, including but not limited to formulating low-carbon transition plans and adaptation measures approved by management, and tracking implementation progress and effectiveness.

(4) Metrics and Targets

In 2024, combining its own business operation reality, BrainAurora set scientific, quantifiable environmental targets and annual execution plans across four major areas: carbon emission management, waste management, energy management, and water resource management, around the dimension of addressing climate change. We established a normalized target review mechanism to review and analyze the completion of targets annually, continuously iterating and optimizing energy-saving and emission-reducing management measures to ensure that various environmental commitments are effective.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

During the reporting period, the Company's greenhouse gas emissions data are shown in the table below. According to the principle of materiality, the scope of key environmental performance indicators covers the Beijing office, Changsha office and Hong Kong office of the Company.

Indicator		Data in 2025	Data in 2024
Greenhouse gases[12]	**Total emissions of greenhouse gases (scope I and II)** (tCO2e)	**146.03**	124.84
	Emission density of greenhouse gases (tCO2e/person)	**0.85**	0.79
	Direct emissions of greenhouse gases (scope I)[13] (tCO2e)	**44.46**	15.25
	In which: oil consumption of official vehicles	**44.46**	15.25
	Direct emission density of greenhouse gases (scope I) (tCO2e/person)	**0.26**	0.10
	Indirect emissions of greenhouse gases (scope II) (tCO2e)	**101.57**	109.59
	In which: purchased electricity	**101.57**	109.59
	Indirect emission density of greenhouse gases (scope II) (tCO2e/person)	**0.59**	0.69
	Scope III greenhouse gas emissions (tCO2e)	**95.03**	/

As the Company is in a phase of business expansion and environmental data coverage has been extended to include the Hong Kong office, we have adopted 2025 as the new base year and formulated the 2026 carbon reduction goal tailored to the current development stage with horizontal comparability.

Goal type	Former goal	New goal
Carbon reduction goal	Reduce total greenhouse gas emissions by 1% by 2025 compared with that in 2024	Taking 2025 as the new base year, reduce total greenhouse gas emissions by 1% by 2026 compared with that in base year

12 Greenhouse gases include carbon dioxide, methane and nitrous oxide. Scope I and scope II carbon emissions are mainly derived from fuels and purchased electricity, and scope III carbon emissions primarily come from Category 6 employee business travel. Greenhouse gases emissions are accounted for and presented in carbon dioxide equivalent. The accounting methodology draws on the GHG Protocol Corporate Accounting and Reporting Standard (《溫室氣體核算體系企業核算與報告標準》), the GHG Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard《溫室氣體核算體系企業價值鏈(範圍3)核算與報告標準》, and the Sixth Assessment Report (《第六次評估報告》) issued by the Intergovernmental Panel on Climate Change (IPCC). Relevant emission factors and parameters are adopted for accounting in accordance with China's Average CO_2 Emissions Factors from Electricity 2023 (《2023年全國電力平均二氧化碳排放因子》) released by the Ministry of Ecology and Environment of the People's Republic of China, the 2019 Refinement to the 2006 IPCC Guidelines for National Greenhouse Gas Inventories (《IPCC 2006年國家溫室氣體列表指南2019修訂版》) published by the IPCC, and the China Products Carbon Footprint Factors Database. During the year, greenhouse gas emission data coverage has been expanded to include the Hong Kong office. The Company's emission density of greenhouse gases, direct emission density of greenhouse gases (scope I) and indirect emission density of greenhouse gases (scope II) are calculated based on the total number of full-time employees.

13 During the year, the usage frequency of official vehicles increased significantly due to business expansion. Accordingly, direct emissions of greenhouse gases (scope I), oil consumption of official vehicles and direct emission density of greenhouse gases (scope I) changed materially compared with 2024.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

IV. TALENT ORIENTATION AND CONCERTED PROGRESS

1. Compliant Employment

The Company always adheres to the core principles of "legal employment, fairness and equality, and standardized management", strictly follows the Labor Law of the People's Republic of China (《中華人民共和國勞動法》), the Labor Contract Law of People's Republic of China (《中華人民共和國勞動合同法》), and other relevant laws and regulations. Combined with the reality of the Company's business development, it formulated the Employee Manual to standardize the whole employment process of employee recruitment, hiring, contract management, and resignation, ensuring that all employment activities are legally compliant, protecting the legitimate rights and interests of employees, and maintaining the Company's employment order.

The Company firmly prohibits the employment of child labor and forced labor, establishes a strict entry identity verification mechanism, and verifies candidates' identity information, labor relations termination certificates, and other relevant materials one by one when employees join, eliminating non-compliant employment phenomena from the source. At the same time, the Company conducts background investigations according to law prior to onboarding for senior professional positions and department head positions involving finance, risk control, legal affairs, and technologies, and issues offer letters after no objections from the background investigations, ensuring compliant recruitment processes and authentic personnel information. In 2025, the Company had no incidents of employing child labor or forced labor.

The Company is committed to creating an equal and diverse workplace environment, adhering to the fair, open, and impartial principles of recruitment, selection, and appointment, eliminating any form of discrimination, explicitly stating that factors such as gender, age, race, religion, disability, etc., do not affect the employment and development opportunities of job seekers, and treating every employee and job seeker fairly. During the recruitment process, we strictly advance according to the recruitment application process, conducting recruitment after departmental application and management meeting decision. Interviews implement a mechanism of two-level interviews + human resources interview, focusing on assessing candidate qualities, professional competencies, and team match, ensuring the recruitment process is standardized and transparent.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

As of the end of 2025, BrainAurora had a total of 179 employees, with female employees accounting for 44.13%. The employees divided by gender, employment type, age, and region are as follows:

Indicator	Data in 2025 (person)	Data in 2024 (person)
By gender		
Male	**100**	95
Female	**79**	86
By employment type		
Full time	**171**	159
Part time	**2**	11
Interns	**6**	11
By age		
Aged 30 and below	**43**	60
Aged 31-50	**133**	120
Aged above 50	**3**	1
By region		
Mainland China	**176**	181
Hong Kong, Macao and Taiwan	**3**	0

The employee turnover rate[14] divided by gender, age and region is as follows:

Indicator	Data in 2025 (%)	Data in 2024 (%)
Employee turnover rate	**30.73**	13.26
By gender		
Male	**19.00**	11.58
Female	**45.57**	15.12
By age		
Aged 30 and below	**69.77**	6.67
Aged 31-50	**18.80**	16.67
Aged above 50	**0.00**	0.00
By region		
Mainland China	**31.25**	13.26
Hong Kong, Macao and Taiwan	**0.00**	0.00

[14] Employee turnover rate is calculated on the basis of the Company's all employees, including part-time employees and employees under other employment types. The scope and methodology for the calculation of employee turnover rate are formulated in compliance with the relevant requirements under the HKEX: Reporting Guidance on Social KPIs. To ensure maintaining consistent statistical standards and year-on-year comparability, we have restated and revised the 2024 historical employee turnover figures in line with the current year's statistical rules, defined coverage and accounting criteria. Due to the organisational structure adjustments of the Company, the overall employee turnover rate, as well as employee turnover rates across all types, saw significant year-on-year changes during the reporting period.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

2. Compensation and Benefits

BrainAurora strictly follows the Labor Law of the People's Republic of China (《中華人民共和國勞動法》), the Social Insurance Law of the People's Republic of China (《中華人民共和國社會保險法》), and other relevant laws and regulations, building a scientific, reasonable, and market-competitive compensation and benefits system. It not only protects employees' statutory rights and interests, but also enhances employees' sense of belonging and happiness through diversified welfare care and performance incentives, helping corporate talent retention and team stability.

The Company always adheres to the compliance bottom line, executing strictly according to national labor laws and regulations and company systems. Employee compensation consists of two parts: base salary and variable salary. The base salary is agreed upon in the labor contract, while the variable salary includes various rewards such as performance, bonuses, and allowances. Based on the Company's operating conditions, departmental performance, and individual work performance, we establish a standardized performance management system. By linking employee performance results with variable salaries, we ensure the fairness and incentivizing nature of compensation distribution, fully mobilizing employees' work enthusiasm.

The Company pays five types of social insurance premiums (pension insurance, unemployment insurance, work-related injury insurance, maternity insurance, and medical insurance) and provident funds for all employees strictly in accordance with national and local policies. At the same time, based on statutory benefits, the Company has built a comprehensive welfare system covering employee health, work-life balance, and career development, reflecting a long-term commitment to employee well-being. In terms of health protection, we provide annual physical examinations for regular employees and matching daily health support; in terms of humanistic care, we provide exclusive benefits at key moments such as employee birthdays, weddings, births, and traditional holidays. We also strictly follow national medical leave regulations to provide compliant recuperation protection and humanistic care for sick employees, helping them recover their health and return to their posts. At the same time, we create an inclusive and friendly working atmosphere through daily care such as afternoon tea and snack supplies; in terms of organizational development, we regularly hold department-level and company-level team-building activities to promote cross-level collaboration and knowledge sharing, strengthening organizational cohesion and employees' sense of belonging.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

3. Health and Safety

BrainAurora always attaches great importance to employee health and workplace safety, strictly follows national production safety and occupational disease prevention laws and regulations, adheres to the principle of "safety first, prevention-oriented, full participation", builds a comprehensive health and safety management system, practically protects the personal safety and physical and mental health of employees, and creates a safe, healthy, and comfortable office environment. The Company establishes and improves the office safety management system, standardizes the management of electricity usage, fire protection, and facilities and equipment in the office area, regularly conducts safety inspections of the office environment, strengthens the promotion of employee safety awareness, and promptly eliminates various potential safety hazards.

We are committed to continuously optimizing the office environment, reasonably planning office areas, ensuring good ventilation and lighting in the office space, and balancing employee office comfort and health needs. At the same time, we actively guide employees to develop healthy working habits, advocate the healthy living concept of reasonable rest and moderate exercise, fully safeguard the physical and mental health of employees, and build a solid talent health foundation for sustainable enterprise development.

As of the end of 2025, the Company had no work-related fatalities for four consecutive years.

4. Development and Training

BrainAurora has established a scientific and perfect employee career development and training system, treating talent cultivation as the core support for the sustainable development of the enterprise. The Company builds a clear career development path for employees. Combining its own operational development needs, and through a combination of system regulation and cultivation mechanism, it provides diversified growth support for employees, balancing individual employee growth and corporate development goals, helping employees realize career value while consolidating the enterprise's talent foundation and improving overall work efficiency and competitiveness.

In terms of career development, the Company formulated the Employee Career Development and Position Rank Management System, systematically establishing three major career development channels: management sequence, technical sequence, and scientific research sequence. The Company adheres to the promotion principle of "fairness, impartiality, and openness". The promotion assessment standards, posting requirements, and evaluation processes of each channel have explicit regulations, insisting on "ability + performance" orientation to ensure that employees with different professional specialties can find development paths suited for them, promoting the rapid growth of talent.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

To support employee career development, the Company has built a comprehensive training system, strictly following the three core principles of "practicality, effectiveness, and targeting", ensuring training content tailored to job needs and genuinely empowers employee ability enhancement and enterprise development.

BrainAurora Training System					
Training Direction	Strategy and future development needs	Corporate culture construction	Reduce talent turnover and develop reserve team capabilities	Internal employee self-capability enhancement and promotion	Establishment and improvement of the internal training guidance system
Training Form	Onboarding Training		On-the-job Training		External Training
	New Employees		Senior Management Middle Management Junior Management		Key Personnel
Training Content	Explain the Company's culture, philosophy, products, rules and regulations, etc.		Cultivate management capabilities, professional skills, and comprehensive professional literacy in "project format"		Participate in professional technical salons, industry summits, and expert lectures to learn cutting-edge concepts and skills

BrainAurora Training System

The Company highly values management talent cultivation and organizational capability enhancement. To continuously strengthen comprehensive management literacy, strategic thinking, team leadership, and collaborative execution capabilities of managements, and build a high-quality management echelon, it systematically conducts specialized training for management capabilities and leadership improvement. As of the end of 2025, the Company had organized a total of 4 special leadership training sessions.



Leadership Training

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

During the reporting period, a total of 155 employees received training. The percentage of trained regular employees divided by gender and employee type is as follows:

Indicator	Data in 2025 (%)	Data in 2024 (%)
Trained regular employees by gender		
Proportion of trained male employees	**44.90**	54.09
Proportion of trained female employees	**55.10**	45.91
Trained regular employees by employee type		
Proportion of trained senior management employees	**12.24**	3.14
Proportion of trained intermediate management employees	**28.57**	17.61
Proportion of trained junior employees	**59.19**	79.25

During the reporting period, the per-capita training duration was 17.75 hours. The per-capita training duration divided by gender and employee type is as follows:

Indicator	Data in 2025 (hour)	Data in 2024 (hour)
Trained regular employees by gender		
Average training hours for male	**16.54**	18.96
Average training hours for female	**18.96**	17.80
Trained regular employees by employee type		
Average training hours for senior management employees	**15.33**	13.33
Average training hours for intermediate management employees	**12.79**	14.28
Average training hours for junior employees	**25.15**	19.55

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

V. WIN-WIN COOPERATION AND JOINT PROGRESS

1. Sustainable Supply Chain

(1) Supplier Quality Management

BrainAurora attaches great importance to supply chain management and is committed to building a comprehensive and process-oriented supplier management system. We strictly abide by national and industry-related laws and regulations such as the Bidding Law of the People's Republic of China (《中華人民共和國招標投標法》) and the Regulation on the Implementation of the Bidding Law of the People's Republic of China (《中華人民共和國招標投標實施條例》), ensuring that procurement work is legally compliant, open, and transparent. Internally, we continuously execute the Company's Procurement Management System, continuously standardizing works across all links including supplier selection, evaluation, assessment, and elimination, clarifying operational standards, responsibility division, and process nodes of each link to ensure rules take effect. During the year, the Company further standardized supply chain management processes, strengthened sustainable supply chain management capabilities, promoted suppliers to jointly realize green development with the Company, and guaranteed the orderly and efficient execution of procurement work.

Supplier management mechanism	Content
Supplier selection	Prioritize key suppliers or standard channel suppliers in the Supplier List.
Supplier introduction	New suppliers must undergo strict qualification review: • Based on the characteristics of the procurement projects, take a differentiated evaluation mechanism, including expert reviews for special projects, cross-departmental review meetings for engineering projects, and professional evaluations for technical procurement in various forms. • The execution department and the review department of procurement shall conduct a comprehensive risk assessment of suppliers, including verifying core information such as legal person and shareholder information, company establishment year, and major litigation records. Unnecessary information such as the ultimate beneficiary in business operations may not be included in the Supplier List.
Supplier management	The Company regularly updates and backs up supplier qualifications, list, archives, and other related data, and makes clear regulations on the storage, updating, and other processes of supplier information to achieve efficient management of suppliers. At the same time, we continuously track the compliance performance and fulfillment capability of suppliers. When we identify that suppliers have operational abnormalities, environmental violations, administrative penalties, legal disputes, are blacklisted by relevant departments, or have poor cooperation, we will promptly remove them from the Supplier List or blacklist them, and activate backup suppliers or develop new suppliers to ensure the continuous provision of high-quality services by the Company and avoid supply chain interruption risks.
Supplier evaluation	The Company evaluates the products, services, environmental and social performance of suppliers based on their cooperation situation, and considers the evaluation results as important reference factors for subsequent cooperation with suppliers. The Company regularly updates the Supplier List and timely cancels cooperation with suppliers with poor cooperation performance to strictly control the quality of suppliers.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

In 2025, the Company conducted on-site evaluations on 11 IT product suppliers and 7 furniture suppliers, focusing on verifying their product quality, service capability, and environmental and social management performance. At the same time, it eliminated 1 supplier with frequent quality problems, continuously optimizing the supplier structure and overall fulfillment level.

(2) Supply Chain ESG Management

BrainAurora highly values the responsibility of a sustainable supply chain, embedding ESG requirements into full-process management, actively guiding and supporting suppliers to carry out ESG management, and prompting them to reduce their own environmental and social impacts. In 2025, the Company took multiple targeted measures to effectively identify and reduce environmental and social-related risks in the supply chain, detailed as follows:

Supplier ESG management mechanism	Content
Key supplier on-site inspection	Focus on inspecting supplier product quality, production environment, safety production protection measures, etc., to ensure the supplier's environmental and social responsibility fulfillment meets the Company's requirements.
Integrate environmental and social performance into supplier selection and assessment	Incorporate environmental protection qualifications and social responsibility fulfillment into supplier entry conditions, giving priority to suppliers with environmental certifications (such as ISO14001 Environmental Management System) and green production qualifications.
Supplier risk dynamic monitoring mechanism	Assign dedicated personnel to track the dynamics of supplier environmental and social risks, regularly collect information on environmental violations, safety production accidents, legal disputes, etc., and establish a risk early warning mechanism. If significant risks are found in a supplier, immediately suspend cooperation and activate alternative suppliers, effectively preventing supply chain disruption risks.

At the same time, the Company deeply practices the green procurement concept, comprehensively integrating green, environmental protection, and low-carbon requirements into the full procurement process, actively promoting suppliers to carry out sustainable development practices. In the procurement process, we proactively guide suppliers to implement product upgrades, prioritize the use of environmentally friendly materials and products meeting national standards, and encourage them to provide degradable, energy-saving, and low-carbon eco-friendly products. At the same time, we vigorously promote a localized procurement strategy, effectively reducing carbon emissions generated in the transportation process by shortening logistics transportation radiuses, supporting green and low-carbon development.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

(3) Supplier Integrity Management

BrainAurora always adheres to the principles of openness, fairness, and impartiality, attaches great importance to the integrity management of partners, and joins hands to build a clean and upright business cooperation ecosystem. The Company signs the Anti-commercial Bribery Agreement with third-party cooperative entities such as key suppliers and service providers, and conducts tracking and supervision of the execution of the agreements. During the year, the Company continuously strengthened the integrity education of procurement personnel, organizing special integrity learning quarterly. The content covers national laws and regulations, the Company's integrity systems, and typical warning cases, practically enhancing the professional integrity awareness and compliance capabilities of procurement personnel. At the same time, we further strengthened integrity control over the entire procurement process, continuously standardizing key links such as bidding, inquiry, and review. To guarantee the effectiveness of integrity management, the Company requires procurement personnel to proactively declare any interests or conflicts of interest with suppliers, strictly execute the duty recusal system, and implement strict confidentiality management over sensitive information during the procurement process.

During the year, the Company found no cooperative parties violating the integrity agreements, nor did it receive any related integrity reports, effectively maintaining the compliance and integrity of the procurement link, and building a healthy and sustainable supply chain cooperative environment.

(4) Supplier Communication

BrainAurora systematically advances a diversified supplier communication mechanism through various forms such as regular online coordination, offline special interviews, and on-site inspections. For all suppliers, we achieve efficient daily coordination through online communication methods like WeChat, email, and video conferences; for core suppliers, we conduct offline special interviews at least once every half year to communicate deeply about key and difficult issues in cooperation; for suppliers with quality, delivery, or environmental issues, the Company assigns dedicated personnel to the site to synergistically troubleshoot, ensuring precise, efficient communication, and closed-loop problem resolution.

Through the diversified communication mechanism, the Company accurately transmits procurement needs, green procurement, and environmental compliance requirements to suppliers, synergistically resolves fulfillment issues like capacity deployment and stocking guarantees, efficiently handles various matters in cooperation, and achieves a 100% problem closed-loop rate. At the same time, we actively collect reasonable suggestions from suppliers in terms of cooperation processes, product optimization, and cost control, promoting both parties to synergistically improve cooperation efficiency and enhance sustainable development capabilities.

Number of suppliers divided by region	Data in 2025 (supplier)
Total number of suppliers	354
Mainland China	302
Hong Kong, Macao and Taiwan	52
Overseas	0

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

2. Public Welfare and Charity

BrainAurora attaches great importance to the practice of social responsibility and is committed to creating value for the places where it operates. In 2025, taking cognitive health public welfare as its core direction, BrainAurora focuses on two key projects: the "Health Guard" public screening and brain health science popularization education, concurrently building an internal employee volunteer service system, rallying the strength of all employees to support social public welfare undertakings, and providing full-process guarantees for various public welfare activities. Our employee volunteers give full play to their professional expertise, actively participating in public welfare screening data arrangement, science popularization material compilation, community activity coordination, on-site order maintenance, and elderly group Q&A assistance, helping various public welfare activities to be implemented solidly and achieve real effects throughout the process, practicing corporate social responsibility with practical actions.

[Case: Health Guard Enters Communities: Brain Health Public Welfare Early Screening Action]
In the field of social assistance, the Company reached a strategic cooperation with the China Volunteers Association to jointly launch the "Health Guard" public screening action. Relying on its independently developed intelligent brain health screening system, the Company goes deep into communities to provide inclusive, medical-grade cognitive impairment early screening services for high-risk groups. It builds a full-chain health guardianship system of "screening – assessment – intervention", promoting the sinking of high-quality screening services to the "last mile" of the grassroots, so that cognitive impairment early screening and prevention benefits more grassroots people.

[Case: Experts Escort Brain Health: Public Welfare Science Popularization Cracks Cognitive Misunderstandings]
In the field of public welfare science popularization, the Company united with authoritative experts in the brain health and rehabilitation fields from multiple Class III Grade A hospitals to carry out brain health public welfare lectures and free clinic activities. The project draws on the multi-disciplinary joint free clinic model, takes "science popularization lecture + practical guidance" as the core form, and popularizes cognitive impairment prevention knowledge and early identification methods to the public through diversified ways such as digital science popularization, special health lecture halls, and expert one-on-one Q&A, breaking social cognitive misunderstandings. The activity effectively raised the public's scientific cognitive level regarding cognitive impairment, practicing corporate social responsibility with practical actions.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

APPENDIX

Appendix 1 Key Performance Table

Quantitative Indicator Breakdown		Indicator Unit (Reference)	Data in 2025	Data in 2024
Category A Environmental				
Waste Gas	Emissions of nitrogen oxides	kg	**130.27**	60.47
	Emissions of sulfur oxides	kg	**0.28**	0.10
	Particulate matter	kg	**12.48**	5.79
Greenhouse Gases	Total emissions of greenhouse gases (scope I + scope II)	tCO_2e	**146.03**	124.84
	Emission density of greenhouse gases (scope I + scope II)	tCO_2e/person	**0.85**	0.79
	Direct emissions of greenhouse gases (scope I)	tCO_2e	**44.46**	15.25
	Direct emission density of greenhouse gases (scope I)	tCO_2e/person	**0.26**	0.10
	Indirect emissions of greenhouse gases (scope II)	tCO_2e	**101.57**	109.59
	Indirect emission density of greenhouse gases (scope II)	tCO_2e/person	**0.59**	0.69
	Indirect emissions of greenhouse gases (scope III)	tCO_2e/person	**95.03**	/
Waste	Total amount of hazardous waste	ton	**0.0375**	0.044
	Density of hazardous waste	kg/person	**0.219**	0.277
	Total amount of non-hazardous waste	ton	**6.2**	0.60
	Density of non-hazardous waste	kg/person	**36.26**	3.774
Use of Resources	Total consumption of comprehensive energy	MWh	**359.99**	263.95
	Direct energy consumption	MWh	**168.56**	59.72
	In which: oil consumption of official vehicles	MWh	**168.56**	59.72
	Indirect energy consumption	MWh	**191.43**	204.23
	In which: purchased electricity	MWh	**191.43**	204.23
	Density of comprehensive energy consumption	MWh/person	**2.11**	1.66
	Daily water consumption	ton	**2,106**	2,377
	Per-capita daily water consumption	ton/person	**12.32**	14.95

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Quantitative Indicator Breakdown			Indicator Unit (Reference)	Data in 2025	Data in 2024
Category B Social					
Employment	Total number of employees		person	**179**	181
	Number of employees by employment type	Full time	person	**171**	159
		Part time	person	**2**	11
		Interns	person	**6**	11
	Number of employees by employee type	Senior management	person	**7**	5
		Intermediate management	person	**29**	28
		Junior employees	person	**143**	148
	Number of employees by gender	Male	person	**100**	95
		Female	person	**79**	86
	Number of employees by age	Aged 30 and below	person	**43**	60
		Aged 31-50	person	**133**	120
		Aged above 50	person	**3**	1
	Number of employees by region	Mainland China	person	**176**	181
		Overseas	person	**0**	0
		Hong Kong, Macao and Taiwan	person	**3**	0
	Number of disabled employees		person	**2**	3
	Employee turnover rate		%	**30.73**	13.26
	Employee turnover rate by gender	Male	%	**19.00**	11.58
		Female	%	**45.57**	15.12
	Employee turnover rate by age	Aged 30 and below	%	**69.77**	6.67
		Aged 31-50	%	**18.80**	16.67
		Aged above 50	%	**0.00**	0.00
	Employee turnover rate by region	Mainland China	%	**31.25**	13.26
		Overseas	%	**0.00**	0.00
		Hong Kong, Macao and Taiwan	%	**0.00**	0.00

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Quantitative Indicator Breakdown			Indicator Unit (Reference)	Data in 2025	Data in 2024
Health and Safety	Number of work-related fatalities occurred in the past three years		person	**0**	0
	Number of workdays lost due to work-related injuries[15]		day	**13**	0
Development and Training	Total training duration for regular employees		hour	**2,751**	2,928.78
	Percentage of trained regular employees by gender	Male	%	**44.90**	54.09
		Female	%	**55.10**	45.91
	Percentage of trained regular employees by employee type	Senior management	%	**12.24**	3.14
		Intermediate management	%	**28.57**	17.61
		Junior employees	%	**59.19**	79.25
	Average training hours for regular employees by gender	Male	hour	**16.54**	18.96
		Female	hour	**18.96**	17.80
	Average training hours for regular employees by employee type	Senior management	hour	**15.33**	13.33
		Intermediate management	hour	**12.79**	14.28
		Junior employees	hour	**25.15**	19.55
Supply Chain Management	Total number of suppliers		supplier	**354**	266
	Number of suppliers by geographical region	Mainland China	supplier	**302**	261
		Hong Kong, Macao and Taiwan	supplier	**52**	5
		Overseas	supplier	**0**	0

[15] The number of workdays lost due to work-related injuries during the year resulted from a traffic accident during an employee's commute, which was not a safety incident related to on-site work operations.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Quantitative Indicator Breakdown			Indicator Unit (Reference)	Data in 2025	Data in 2024
Product Responsibility	Percentage of recalled products due to safety and health reasons out of total products sold or shipped		%	**0**	0
	Number of product and service related complaints received		time	**1**	2
	Product and service related complaints resolution rate		%	**100**	100
	Total amount of intellectual property retained		piece	**345**	321
	Amount of intellectual property retained	Number of patents	piece	**72**	65
		Number of trademarks	piece	**188**	178
		Number of software copyrights	piece	**85**	78
Anti-corruption	Number of concluded corruption litigation cases		case	**0**	0
	Proportion of directors participating in anti-corruption training		%	**100**	100
	Proportion of employees participating in anti-corruption training		%	**100**	100
Community Investment	Public welfare donation amount		RMB10,000	**0**	/
	Number of employees participating in volunteer service		person-time	**0**	/
	Total duration of volunteer service contributed by employees		hour	**0**	/

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Appendix 2 Index Table of the Environmental, Social and Governance Reporting Code of the Hong Kong Stock Exchange

Environmental, Social and Governance Aspects as well as General Disclosures and Key Performance Indicators (KPIs)			Section/Remarks
A. Environmental			
A1: Emissions	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to air emissions, discharges into water and land, and generation of hazardous and non-hazardous waste.	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Strengthening Emission Control
	A1.1	Types of emissions and respective emissions data	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Strengthening Emission Control Appendix 1 Key Performance Table
	A1.3	Total hazardous waste produced and intensity	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Strengthening Emission Control Appendix 1 Key Performance Table
	A1.4	Total non-hazardous waste produced and intensity	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Strengthening Emission Control Appendix 1 Key Performance Table
	A1.5	Description of emission target(s) set and steps taken to achieve them	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Strengthening Emission Control
	A1.6	Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Strengthening Emission Control

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Environmental, Social and Governance Aspects as well as General Disclosures and Key Performance Indicators (KPIs)			Section/Remarks
A2: Use of Resources	General Disclosure	Policies on the efficient use of resources, including energy, water and other raw materials	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Optimizing the Resource Utilization
	A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total and intensity	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Optimizing the Resource Utilization Appendix 1 Key Performance Table
	A2.2	Total water consumption and intensity	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Optimizing the Resource Utilization Appendix 1 Key Performance Table
	A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Optimizing the Resource Utilization
	A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, and water efficiency target(s) set and steps taken to achieve them	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Optimizing the Resource Utilization
	A2.5	Total packaging material used for finished products and per unit produced	Not applicable
A3: The Environment and Natural Resources	General Disclosure	Policies on minimizing the issuer's significant impacts on the environment and natural resources	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Optimizing the Resource Utilization
	A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Optimizing the Resource Utilization

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Environmental, Social and Governance Aspects as well as General Disclosures and Key Performance Indicators (KPIs)			Section/Remarks
B. Social			
B1: Employment	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare	TALENT ORIENTATION AND CONCERTED PROGRESS
	B1.1	Total workforce by gender, employment type, age group and geographical region	TALENT ORIENTATION AND CONCERTED PROGRESS • Compliant Employment Appendix 1 Key Performance Table
	B1.2	Employee turnover rate by gender, age group and geographical region	TALENT ORIENTATION AND CONCERTED PROGRESS • Compliant Employment Appendix 1 Key Performance Table
B2: Health and Safety	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards	TALENT ORIENTATION AND CONCERTED PROGRESS • Health and Safety
	B2.1	Number and rate of work-related fatalities occurred in each of the past three years	TALENT ORIENTATION AND CONCERTED PROGRESS • Health and Safety Appendix 1 Key Performance Table
	B2.2	Lost days due to work injury	TALENT ORIENTATION AND CONCERTED PROGRESS • Health and Safety Appendix 1 Key Performance Table
	B2.3	Description of occupational health and safety measures adopted, and how they are implemented and monitored	TALENT ORIENTATION AND CONCERTED PROGRESS • Health and Safety

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Environmental, Social and Governance Aspects as well as General Disclosures and Key Performance Indicators (KPIs)			Section/Remarks
B3: Development and Training	General Disclosure	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities	TALENT ORIENTATION AND CONCERTED PROGRESS • Development and Training
	B3.1	The percentage of employees trained by gender and employee category	TALENT ORIENTATION AND CONCERTED PROGRESS • Development and Training Appendix 1 Key Performance Table
	B3.2	The average training hours completed per employee by gender and employee category	TALENT ORIENTATION AND CONCERTED PROGRESS • Development and Training Appendix 1 Key Performance Table
B4: Labor Standards	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labor.	TALENT ORIENTATION AND CONCERTED PROGRESS • Compliant Employment
	B4.1	Description of measures to review recruitment practices to avoid child and forced labor	TALENT ORIENTATION AND CONCERTED PROGRESS • Compliant Employment
	B4.2	Description of steps taken to eliminate such practices when discovered	TALENT ORIENTATION AND CONCERTED PROGRESS • Compliant Employment
B5: Supply Chain Management	General Disclosure	Policies on managing environmental and social risks of the supply chain	WIN-WIN COOPERATION AND JOINT PROGRESS • Sustainable Supply Chain
	B5.1	Number of suppliers by geographical region	WIN-WIN COOPERATION AND JOINT PROGRESS • Sustainable Supply Chain Appendix 1 Key Performance Table
	B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored	WIN-WIN COOPERATION AND JOINT PROGRESS • Sustainable Supply Chain
	B5.3	Description of practices used to identify environmental and social risks along each step of the supply chain, and how they are implemented and monitored	WIN-WIN COOPERATION AND JOINT PROGRESS • Sustainable Supply Chain
	B5.4	Description of practices used to promote environmentally friendly products and services when selecting suppliers, and how they are implemented and monitored	WIN-WIN COOPERATION AND JOINT PROGRESS • Sustainable Supply Chain

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Environmental, Social and Governance Aspects as well as General Disclosures and Key Performance Indicators (KPIs)			Section/Remarks
B6: Product Responsibility	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress	HEART AND BRAIN PROTECTION WITH QUALITY FIRST • Product Quality and Safety
	B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons	HEART AND BRAIN PROTECTION WITH QUALITY FIRST • Product Quality and Safety Appendix 1 Key Performance Table
	B6.2	Number of products and service-related complaints received and how they are dealt with	HEART AND BRAIN PROTECTION WITH QUALITY FIRST • Product Quality and Safety Appendix 1 Key Performance Table
	B6.3	Description of practices relating to observing and protecting intellectual property rights	HEART AND BRAIN PROTECTION WITH QUALITY FIRST • Product Quality and Safety
	B6.4	Description of quality assurance process and recall procedures	HEART AND BRAIN PROTECTION WITH QUALITY FIRST • Product Quality and Safety
	B6.5	Description of consumer data protection and privacy policies, and how they are implemented and monitored	HEART AND BRAIN PROTECTION WITH QUALITY FIRST • Product Quality and Safety

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Environmental, Social and Governance Aspects as well as General Disclosures and Key Performance Indicators (KPIs)			Section/Remarks
B7: Anti-corruption	General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering	STABLE AND LONG-TERM DEVELOPMENT BASED ON COMPLIANCE • Business Ethics and Anti-Corruption
	B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases	STABLE AND LONG-TERM DEVELOPMENT BASED ON COMPLIANCE • Business Ethics and Anti-Corruption Appendix 1 Key Performance Table
	B7.2	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored	STABLE AND LONG-TERM DEVELOPMENT BASED ON COMPLIANCE • Business Ethics and Anti-Corruption
	B7.3	Description of anti-corruption training provided to directors and staff	STABLE AND LONG-TERM DEVELOPMENT BASED ON COMPLIANCE • Business Ethics and Anti-Corruption Appendix 1 Key Performance Table
B8: Community Investment	General Disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests	WIN-WIN COOPERATION AND JOINT PROGRESS • Public Welfare and Charity
	B8.1	Focus areas of contribution	WIN-WIN COOPERATION AND JOINT PROGRESS • Public Welfare and Charity Appendix 1 Key Performance Table
	B8.2	Resources contributed to the focus area	WIN-WIN COOPERATION AND JOINT PROGRESS • Public Welfare and Charity Appendix 1 Key Performance Table

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Climate-related Disclosure Indicators		Section
Governance	Disclose information on the governance body or individuals responsible for overseeing climate-related risks and opportunities, including how skill competencies are determined, the frequency and methods by which they are informed of risks and opportunities, how these are considered in decision-making, oversight of target setting and progress, and the role of management in relevant processes and integration with internal functions	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Addressing Climate Change
Strategy — Business Model and Value Chain	Describe the current and anticipated impacts of climate-related risks and opportunities on the business model and value chain, identifying concentrated areas	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Addressing Climate Change
Strategy — Strategy and Decision-making	Disclose strategies and plans to address risks and opportunities, including changes to the business model, adaptation or mitigation efforts, transition plans, methods for achieving climate targets, and resource allocation plans for actions and progress of previous plans	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Addressing Climate Change
Strategy — Financial Position, Financial Performance, and Cash Flows	Disclose the current and anticipated financial impacts of climate-related risks and opportunities on the issuer's financial position, financial performance, and cash flows during the reporting period	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Addressing Climate Change
Strategy — Resilience	Disclose the Company's assessment of its climate resilience and the conduct of climate-related scenario analysis	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Addressing Climate Change
Risk Management	Disclose the processes and related policies used to identify, assess, prioritize, and monitor climate-related risks and opportunities, and how these are integrated into the Company's overall risk management process	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Addressing Climate Change

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Climate-related Disclosure Indicators		Section
Metrics and Targets — Greenhouse Gas Emissions	Disclose the total absolute Scope I, Scope II, and Scope III greenhouse gas emissions during the reporting period, explaining measurement methodologies, inputs, assumptions, and reasons for changes. Disclose Scope II emissions on a location-based basis and the categories included in Scope III	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Addressing Climate Change
Metrics and Targets — Climate-related Targets	Disclose qualitative and quantitative climate-related targets, including set indicators, objectives, scope, period, base period, interim targets, target types, and alignment with international agreements. Disclose methods for verifying targets, indicators for monitoring progress, and performance and trend analysis. For greenhouse gas emission targets, specify the gases covered, emission scopes, and whether they are gross or net targets	GUARDING GREEN DEVELOPMENT AND FULFILLING RESPONSIBILITIES • Addressing Climate Change